[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 445
41. Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):354-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome.
  • PURPOSE: To assess survival, local control, and toxicity of intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the anal canal.
  • CONCLUSIONS: In this hypothesis-generating analysis, the acute toxicity and clinical outcome with IMRT in the treatment of anal cancer is encouraging.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Radiotherapy, Conformal / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168830.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


42. Ferrigno R, Nakamura RA, Dos Santos Novaes PE, Pellizzon AC, Maia MA, Fogarolli RC, Salvajoli JV, Filho WJ, Lopes A: Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. Int J Radiat Oncol Biol Phys; 2005 Mar 15;61(4):1136-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
  • PURPOSE: This retrospective analysis reports the results on patients with anal canal carcinoma treated by combined radiotherapy and chemotherapy.
  • METHODS AND MATERIALS: Between March 1993 and December 2001, 43 patients with anal canal carcinoma were treated with radiochemotherapy at the Hospital do Cancer A.C. Camargo.
  • CONCLUSIONS: This analysis suggests that the treatment scheme employed was effective for anal sphincter preservation and local control; however, the incidence of distant metastases was relatively high.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / drug therapy. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752894.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


43. Shiozawa M, Nishimura K, Nonaka T, Yoshii T, Nakayama N, Motohashi O, Takagi S, Nakayama Y, Akaike M: [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas]. Gan To Kagaku Ryoho; 2010 Dec;37(13):2941-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three cases of radiotherapy combined with S-1 and mitomycin C for anal canal squamous cell carcinomas].
  • We report three cases of anal canal squamous cell carcinoma treated with radiotherapy combined with S-1 and mitomycin C(MMC).
  • These results suggested that this treatment schedule was safe and effective for anal canal carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy
  • [MeSH-minor] Administration, Oral. Aged. Anal Canal. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Female. Fluorouracil / administration & dosage. Humans. Injections, Intravenous. Middle Aged. Mitomycin / administration & dosage. Radiotherapy Dosage

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160276.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


4
Advertisement
4. Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F, Shen J, Zhang Y, Bai J, Zhou M, Miao D, Chen Q: Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol Cell Proteomics; 2008 Sep;7(9):1639-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma.
  • This work demonstrates that a comprehensive strategy of proteomics identification combined with further validation and detailed functional analysis should be adopted in the field of cancer biomarker discovery.
  • A comparative proteomics approach was utilized to identify differentially expressed proteins in 10 oral squamous carcinoma samples paired with their corresponding normal tissues.
  • A total of 52 significantly and consistently altered proteins were identified with eight of these being reported for the first time in oral squamous carcinoma.
  • RACK1 was demonstrated to be up-regulated in cancer at both the mRNA and protein levels.
  • Immunohistochemical examination showed that the enhanced expression of RACK1 was correlated with the severity of the epithelial dysplasia as well as clinical stage, lymph node involvement, and recurrence, which are known indicators of a relatively poor prognosis in oral squamous carcinoma patients.
  • RNA interference specifically targeted to silence RACK1 could initiate apoptosis of oral squamous carcinoma cells.
  • Taken together, the results indicate that RACK1 is up-regulated in oral squamous carcinoma, not only being closely related to cell proliferation and apoptosis but also linked to clinical invasiveness and metastasis in carcinogenesis.
  • The observations suggest that RACK1 may be a potential biomarker for early diagnosis, prognosis, and monitoring in the therapy of oral squamous carcinoma.
  • Further this comprehensive strategy could be used for identifying other differentially expressed proteins that have potential to be candidate biomarkers of oral squamous carcinoma.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Proteomics. 2003 Jun;2(6):378-87 [12813140.001]
  • [Cites] Proteomics. 2004 Jan;4(1):271-8 [14730689.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:295-305 [15251975.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5232-6 [15289328.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):5-11 [15496962.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]
  • [Cites] Anal Chem. 2005 May 1;77(9):2745-55 [15859589.001]
  • [Cites] Med J Aust. 2005 Jun 6;182(11):575-9 [15938685.001]
  • [Cites] Head Neck. 2005 Nov;27(11):995-1003 [16200629.001]
  • [Cites] Electrophoresis. 2006 Apr;27(7):1417-23 [16568407.001]
  • [Cites] Proteomics. 2006 Apr;6 Suppl 1:S262-71 [16534743.001]
  • [Cites] J Mol Neurosci. 2006;29(1):55-63 [16757810.001]
  • [Cites] Exp Mol Med. 2006 Jun 30;38(3):203-9 [16819278.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2092-101 [16893879.001]
  • [Cites] Clin Chim Acta. 2007 Feb;376(1-2):101-7 [16889763.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Apr;133(4):253-61 [17136347.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):309-15 [17384585.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2143-51 [17451265.001]
  • [Cites] Mol Cell Proteomics. 2007 Jun;6(6):987-99 [16829691.001]
  • [Cites] Eur J Biochem. 2000 Jun;267(12):3891-901 [10849009.001]
  • [Cites] FASEB J. 2000 Dec;14(15):2549-58 [11099474.001]
  • [Cites] Virology. 2001 Apr 25;283(1):7-18 [11312657.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20346-56 [11279199.001]
  • [Cites] Cell Signal. 2001 Jul;13(7):507-13 [11516626.001]
  • [Cites] Dis Markers. 2001;17(2):49-57 [11673651.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2345-65 [11884618.001]
  • [Cites] Head Neck. 2002 Feb;24(2):165-80 [11891947.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):698-704 [11902541.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Biol Chem. 2002 Jun 14;277(24):22073-84 [11934885.001]
  • [Cites] Mol Pharmacol. 2002 Dec;62(6):1261-73 [12435793.001]
  • [Cites] J Virol. 2002 Dec;76(24):12676-82 [12438593.001]
  • (PMID = 18458027.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R21 AA021205
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GNB2L1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2556024
  •  go-up   go-down


45. de Bree E, van Ruth S, Dewit LG, Zoetmulder FA: High risk of colostomy with primary radiotherapy for anal cancer. Ann Surg Oncol; 2007 Jan;14(1):100-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High risk of colostomy with primary radiotherapy for anal cancer.
  • BACKGROUND: Radiotherapy (RT) has become the primary treatment of choice for anal cancer in an effort to avoid colostomy.
  • RESULTS: Totally, 28 patients (34%) required creation of a colostomy after primary RT for local failure or treatment-related complications during a mean follow-up period of 39 months.
  • CONCLUSIONS: In approximately one-third of the patients treated by anal sphincter saving management with curative aimed primary RT, the creation of a colostomy appeared to be necessary for RT complications and local treatment failure.
  • Therefore, patients should be well informed regarding the considerable risk of need for colostomy after RT for anal cancer.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Colostomy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17066231.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A; 2007 Jan 16;104(3):973-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
  • Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells.
  • We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples.
  • We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo.
  • Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin.
  • BMI1 has been demonstrated to play a role in self-renewal in other stem cell types and to be involved in tumorigenesis.
  • Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1999;19(2):53-8 [10746434.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):601-2 [11207357.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Gene Ther. 2002 May;9(10):606-12 [12032706.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2256-9 [12215650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):175-9 [14722607.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86 [15375804.001]
  • [Cites] J Pathol. 1985 Apr;145(4):329-40 [3889247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 [1373493.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1579-89 [15897275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • (PMID = 17210912.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / 5P50 CA 097248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44
  • [Other-IDs] NLM/ PMC1783424
  •  go-up   go-down


47. Steller W, Einenkel J, Horn LC, Braumann UD, Binder H, Salzer R, Krafft C: Delimitation of squamous cell cervical carcinoma using infrared microspectroscopic imaging. Anal Bioanal Chem; 2006 Jan;384(1):145-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delimitation of squamous cell cervical carcinoma using infrared microspectroscopic imaging.
  • Infrared (IR) spectroscopic imaging coupled with microscopy has been used to investigate thin sections of cervix uteri encompassing normal tissue, precancerous structures, and squamous cell carcinoma.
  • In the second step, analysis in the spectral window 1420-1480 cm(-1) enables, for the first time, IR spectroscopic distinction between the basal layer, dysplastic lesions and squamous cell carcinoma within a particular sample.
  • The joint application of IR microspectroscopic imaging and multivariate spectral processing combines diffraction-limited lateral optical resolution on the single cell level with highly specific and sensitive spectral classification on the molecular level.
  • Compared with previous reports our approach constitutes a significant progress in the development of optical molecular spectroscopic techniques toward an additional diagnostic tool for the early histopathological characterization of cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Spectrophotometry, Infrared / methods. Uterine Cervical Neoplasms / pathology


48. Yildiz PB, Shyr Y, Rahman JS, Wardwell NR, Zimmerman LJ, Shakhtour B, Gray WH, Chen S, Li M, Roder H, Liebler DC, Bigbee WL, Siegfried JM, Weissfeld JL, Gonzalez AL, Ninan M, Johnson DH, Carbone DP, Caprioli RM, Massion PP: Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer. J Thorac Oncol; 2007 Oct;2(10):893-901
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer.
  • PURPOSE: There is a critical need for improvements in the noninvasive diagnosis of lung cancer.
  • We hypothesized that matrix-assisted laser desorption ionization mass spectrometry (MALDI MS) analysis of the most abundant peptides in the serum may distinguish lung cancer cases from matched controls.
  • The serum signature was associated with the diagnosis of lung cancer independently of gender, smoking status, smoking pack-years, and C-reactive protein levels.
  • From this signature, we identified three discriminatory features as members of a cluster of truncated forms of serum amyloid A.
  • CONCLUSIONS: We found a serum proteomic profile that discriminates lung cancer from matched controls.
  • Proteomic analysis of unfractionated serum may have a role in the noninvasive diagnosis of lung cancer and will require methodological refinements and prospective validation to achieve clinical utility.

  • Genetic Alliance. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909350.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / R33 CA086243; United States / NCI NIH HHS / CA / P50 CA090440; United States / NCI NIH HHS / CA / P50 CA090949-07; United States / NCI NIH HHS / CA / P50 CA90440; United States / NCI NIH HHS / CA / P50 CA090949; United States / NCI NIH HHS / CA / P30 CA068485; United States / NCI NIH HHS / CA / P50 CA90949; United States / NCI NIH HHS / CA / U01 CA114771-04; United States / NCI NIH HHS / CA / U01 CA114771; United States / NCI NIH HHS / CA / 5R33CA86243
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS637970; NLM/ PMC4220686
  •  go-up   go-down


49. Gretschel S, Warnick P, Bembenek A, Dresel S, Koswig S, String A, Hünerbein M, Schlag PM: Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal. Eur J Surg Oncol; 2008 Aug;34(8):890-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic mapping and sentinel lymph node biopsy in epidermoid carcinoma of the anal canal.
  • AIM: Although 15-25% of patients with anal cancer present with superficial inguinal lymph node metastases but the routine application of groin irradiation is controversial because of serious side effects.
  • METHODS: Forty patients with anal cancer underwent 1 ml Tc(99m)-Nanocolloid injection in four sites around the tumour.
  • CONCLUSIONS: Inguinal sentinel node biopsy in anal cancer is efficient and could assist in the decision for inguinal radiation.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / secondary. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18178364.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0 / Technetium Tc 99m Aggregated Albumin
  •  go-up   go-down


50. Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ: Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem; 2008 Jan;56(1):57-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Osteopontin (OPN) is an adhesive, matricellular glycoprotein, whose expression is elevated in many types of cancer and has been shown to facilitate tumorigenesis in vivo.
  • To understand the role of OPN in human skin cancer, this study is designed to determine whether OPN is expressed in premalignant [solar/actinic keratosis (AK)] and in malignant skin lesions such as squamous cell carcinomas (SCC) and basal cell carcinomas (BCC), as well as in normal skin exposed or not exposed to sunlight.
  • In sunlight-exposed normal skin, OPN is minimally expressed in the basal cell layer, but in contrast to those not exposed to sunlight, OPN is more prominent in the spinous cell layer with increasing intensity toward the granular cell layer.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Exp Cell Res. 1995 Feb;216(2):335-41 [7843278.001]
  • [Cites] Am J Pathol. 1995 Jan;146(1):95-100 [7856741.001]
  • [Cites] Arch Dermatol. 1995 Jul;131(7):796-800 [7611795.001]
  • [Cites] Matrix Biol. 1995 Jul;14(7):553-60 [8535605.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):78-81 [8782823.001]
  • [Cites] Lung Cancer. 1996 Nov;15(3):311-23 [8959677.001]
  • [Cites] Arch Biochem Biophys. 1997 Jul 15;343(2):157-63 [9224725.001]
  • [Cites] Cancer Invest. 1998;16(5):329-44 [9627681.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] J Bone Miner Res. 1998 Jul;13(7):1101-11 [9661074.001]
  • [Cites] Clin Cancer Res. 1997 Apr;3(4):605-11 [9815727.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):640-6 [9818175.001]
  • [Cites] Hum Pathol. 1998 Nov;29(11):1250-4 [9824103.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1087-90 [9870857.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Mar;47(3):802-6 [16505010.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):624-32; discussion 624-32 [16567167.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):233-46 [16816376.001]
  • [Cites] Arch Dermatol. 2006 Jul;142(7):900-6 [16847207.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7119-27 [16849558.001]
  • [Cites] Zhonghua Wei Chang Wai Ke Za Zhi. 2007 Jan;10(1):73-6 [17253181.001]
  • [Cites] J Histochem Cytochem. 2007 Apr;55(4):403-9 [17210923.001]
  • [Cites] Pathol Res Pract. 1999;195(11):733-9 [10605692.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):156-63 [10901364.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 19;280(2):460-5 [11162539.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4060-6 [11751502.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):270-8 [11807984.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1554-8 [11886522.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2271-7 [10473115.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Dent Mater J. 2004 Dec;23(4):650-5 [15688734.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3958-65 [15867397.001]
  • [Cites] Kidney Int. 2005 Jul;68(1):155-66 [15954904.001]
  • [Cites] Trends Cell Biol. 2006 Feb;16(2):79-87 [16406521.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Exp Cell Res. 2007 Apr 1;313(6):1149-60 [17306792.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2840-50 [17160024.001]
  • [Cites] Bone. 2007 Jun;40(6):1517-28 [17395559.001]
  • [Cites] Diabetes. 2007 Jun;56(6):1662-70 [17360982.001]
  • [Cites] Clin Exp Metastasis. 2003;20(1):77-84 [12650610.001]
  • [Cites] Cancer. 2003 Jul 1;98(1):119-27 [12833464.001]
  • [Cites] Protein Expr Purif. 2003 Aug;30(2):238-45 [12880773.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1749-58 [12919959.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):487-91 [15006928.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1877-81 [15138464.001]
  • [Cites] J Dent Res. 2004 Sep;83(9):664-70 [15329369.001]
  • [Cites] J Surg Res. 2004 Oct;121(2):228-41 [15501463.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Oct;83(19):7182-6 [3532105.001]
  • [Cites] J Biol Chem. 1987 Feb 25;262(6):2900-7 [3469201.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Exp Med. 1989 Jul 1;170(1):145-61 [2787378.001]
  • [Cites] Genomics. 1989 Aug;5(2):375-7 [2571582.001]
  • [Cites] Anticancer Res. 1989 Sep-Oct;9(5):1291-9 [2686530.001]
  • [Cites] Genomics. 1990 Aug;7(4):491-502 [1974876.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2144-50 [2009532.001]
  • [Cites] Mol Carcinog. 1991;4(3):196-202 [2064725.001]
  • [Cites] J Bone Miner Res. 1992 Jul;7(7):743-54 [1642143.001]
  • [Cites] Mol Biol Cell. 1992 Oct;3(10):1169-80 [1421573.001]
  • [Cites] J Histochem Cytochem. 1994 Mar;42(3):351-61 [8308252.001]
  • [Cites] Endocrinology. 1994 Sep;135(3):863-9 [8070379.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):610-23 [8080043.001]
  • [Cites] Cancer. 1995 Jan 15;75(2 Suppl):607-12 [7804986.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):64-9 [7837792.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1061-9 [9342184.001]
  • [Cites] J Cell Biochem. 1997 Dec 1;67(3):386-96 [9361193.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1468-78 [9525990.001]
  • [Cites] Int J Cancer. 1998 Apr 17;79(2):127-32 [9583725.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23280-5 [8083234.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1671-9 [11926891.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] J Am Soc Nephrol. 2002 May;13(5):1210-8 [11961008.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):506-12 [12209742.001]
  • (PMID = 17938278.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090920; United States / NCI NIH HHS / CA / R01 CA90920
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2323122
  •  go-up   go-down


51. Haboubi N: Anal cancer; do we all have a common treatment strategy? Colorectal Dis; 2009 Nov;11(9):891-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer; do we all have a common treatment strategy?
  • [MeSH-major] Adenocarcinoma / pathology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832862.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  •  go-up   go-down


52. Oblak I, Petric P, Anderluh F, Velenik V, Hudej R, Fras AP: Anal cancer chemoirradiation with curative intent - a single institution experience. Neoplasma; 2009;56(2):150-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer chemoirradiation with curative intent - a single institution experience.
  • Results of radiochemotherapy in 50 patients with squamous cell carcinoma of the anal canal, treated with radical radiochemotherapy between January 2003 and September 2007, at the Institute of Oncology Ljubljana are presented.
  • Late anal stenosis, chronic ulceration and grade 2-3 incontinence developed in 3 (6 %), 2 (4 %) and 5 (10 %) of colostomy-free survivors, respectively.
  • </p> KEYWORDS: anal cancer, radiochemotherapy, survival, toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239330.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Ghouti L, Houvenaeghel G, Moutardier V, Giovannini M, Magnin V, Lelong B, Bardou VJ, Delpero JR: Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer. Dis Colon Rectum; 2005 Jan;48(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage abdominoperineal resection after failure of conservative treatment in anal epidermoid cancer.
  • PURPOSE: Radiotherapy alone or with combined chemotherapy is the first therapeutic option for epidermoid carcinoma of the anal canal.
  • CONCLUSIONS: Despite high incidence of perineal morbidity, salvage abdominoperineal resection for epidermoid carcinomas of the anal canal has a high long-term survival rate.
  • [MeSH-major] Abdomen / surgery. Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Perineum / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690652.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Manoharan S, Kavitha K, Balakrishnan S, Rajalingam K: Clerodendron inerme protects cellular integrity during 7,12-dimethylbenz[A]-anthracene induced hamster buccal pouch carcinogenesis. Afr J Tradit Complement Altern Med; 2008 Jan 22;5(2):213-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral squamous cell carcinoma was induced in the buccal pouch of Syrian golden hamsters by painting with 0.5% DMBA in liquid paraffin thrice a week for 14 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 1973 Mar;19(3):338-40 [4347544.001]
  • [Cites] J Biol Chem. 1948 Sep;175(2):595-603 [18880756.001]
  • [Cites] Biochem Biophys Res Commun. 1980 Jan 29;92(2):631-7 [6766724.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer Detect Prev. 1998;22(3):237-40 [9618045.001]
  • [Cites] Int J Mol Med. 2000 Feb;5(2):201-5 [10639602.001]
  • [Cites] Oral Dis. 2000 Mar;6(2):65-74 [10702782.001]
  • [Cites] J Hematother Stem Cell Res. 2000 Apr;9(2):247-55 [10813538.001]
  • [Cites] J Dent Educ. 2001 Apr;65(4):328-39 [11336118.001]
  • [Cites] Jpn J Pharmacol. 2001 Jul;86(3):302-9 [11488430.001]
  • [Cites] Clin Chim Acta. 2002 Dec;326(1-2):143-9 [12417105.001]
  • [Cites] Clin Biochem. 2003 Feb;36(1):61-5 [12554062.001]
  • [Cites] Pharmacol Res. 2003 Aug;48(2):167-73 [12798669.001]
  • [Cites] J Biol Chem. 1957 May;226(1):497-509 [13428781.001]
  • [Cites] Clin Chim Acta. 2004 Jan;339(1-2):91-6 [14687898.001]
  • [Cites] Biomed Pharmacother. 2004 May;58(4):264-7 [15183854.001]
  • [Cites] J Lab Clin Med. 1950 Jan;35(1):155-60 [15400638.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Clin Invest. 1947 Jul;26(4):636-40 [16695456.001]
  • [Cites] Singapore Med J. 2006 Dec;47(12):1038-43 [17139399.001]
  • [Cites] Clin Chim Acta. 1973 Jun 28;46(2):105-11 [4745354.001]
  • (PMID = 20161940.001).
  • [ISSN] 2505-0044
  • [Journal-full-title] African journal of traditional, complementary, and alternative medicines : AJTCAM
  • [ISO-abbreviation] Afr J Tradit Complement Altern Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  • [Other-IDs] NLM/ PMC2816544
  • [Keywords] NOTNLM ; Clerodendron inerme / DMBA / Oral cancer / glycoconjugates / hamster / lipids / osmotic fragility
  •  go-up   go-down


55. Atkinson DM, Clarke MJ, Mladek AC, Carlson BL, Trump DP, Jacobson MS, Kemp BJ, Lowe VJ, Sarkaria JN: Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts. Head Neck; 2008 Jun;30(6):790-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Using fluorodeoxythymidine to monitor anti-EGFR inhibitor therapy in squamous cell carcinoma xenografts.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8558-64 [16951168.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3331-4 [12067968.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2681-7 [12750297.001]
  • [Cites] Gut. 2003 Nov;52(11):1602-6 [14570730.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):2027-32 [14660729.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] Cell Res. 2004 Aug;14(4):295-302 [15353126.001]
  • [Cites] Acta Biol Med Ger. 1972;29(4):483-94 [4347226.001]
  • [Cites] J Biol Chem. 1991 May 15;266(14):9032-8 [2026611.001]
  • [Cites] Biochem Pharmacol. 1992 Jul 22;44(2):199-204 [1322661.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Nucl Med. 2005 Jan;46(1):114-20 [15632041.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3003-10 [15833824.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):11-9 [11790855.001]
  • (PMID = 18286491.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / R21 CA104310; United States / NCI NIH HHS / CA / CA0108961; United States / NCI NIH HHS / CA / CA104310; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / U10 CA025224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Dideoxynucleosides; 0 / Fluorine Radioisotopes; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PG53R0DWDQ / alovudine; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ NIHMS548870; NLM/ PMC3942889
  •  go-up   go-down


56. Jongen J: Letter to the editor concerning "HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN)" by Varnai et al. (Int J Colorectal Dis 21:135-142, 2006). Int J Colorectal Dis; 2007 Oct;22(10):1289
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Letter to the editor concerning "HPV in anal squamous cell carcinoma and anal intraepithelial neoplasia (AIN)" by Varnai et al. (Int J Colorectal Dis 21:135-142, 2006).
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Anus Neoplasms / virology. Carcinoma in Situ / virology. Carcinoma, Squamous Cell / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Int J Colorectal Dis. 2006 Mar;21(2):135-42 [15864603.001]
  • (PMID = 16703315.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] Germany
  •  go-up   go-down


57. Amano K, Ishibashi K, Nakada H, Okada N, Miyazaki T, Gonda T, Ishida H, Takahashi T: [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report]. Gan To Kagaku Ryoho; 2007 Nov;34(12):2025-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the anal canal in the elderly showing complete response following radiotherapy--a case report].
  • We reported an elderly case of squamous cell carcinoma of the anal canal which showed complete response following radiotherapy alone.
  • An 86-year-old man complaining of anal bleeding and pain was admitted.
  • Biopsy revealed squamous cell carcinoma.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18219887.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Sameer AS, Chowdri NA, Syeed N, Banday MZ, Shah ZA, Siddiqi MA: SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene. BMC Cancer; 2010;10:300
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SMAD4--molecular gladiator of the TGF-beta signaling is trampled upon by mutational insufficiency in colorectal carcinoma of Kashmiri population: an analysis with relation to KRAS proto-oncogene.
  • BACKGROUND: The development and progression of colorectal cancer has been extensively studied and the genes responsible have been well characterized.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Colorectal Neoplasms / genetics. Mutation. Proto-Oncogene Proteins / genetics. Signal Transduction. Smad4 Protein / genetics. Transforming Growth Factor beta / metabolism. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Mol Cell Biochem. 2009 Dec;332(1-2):51-8 [19513816.001]
  • [Cites] Carcinogenesis. 1992 Aug;13(8):1331-5 [1499084.001]
  • [Cites] Curr Opin Oncol. 1993 Jan;5(1):123-9 [8427884.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2527-30 [8653691.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):347-9 [8673135.001]
  • [Cites] Genes Dev. 2006 Nov 15;20(22):3130-46 [17114584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):21-62 [16904831.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):295-308 [17384584.001]
  • [Cites] Environ Health Perspect. 1995 Nov;103 Suppl 8:205-8 [8741784.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2578-80 [9205057.001]
  • [Cites] J Pathol. 1998 Jun;185(2):130-8 [9713338.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Oncogene. 1999 Mar 18;18(11):2033-7 [10208426.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Int J Cancer. 2005 Aug 10;116(1):62-8 [15761872.001]
  • [Cites] Am Surg. 2005 Apr;71(4):336-43 [15943410.001]
  • [Cites] Gut. 2005 Sep;54(9):1283-6 [15843421.001]
  • [Cites] Oncogene. 2005 Aug 29;24(37):5742-50 [16123807.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]
  • [Cites] Int J Biol Sci. 2010;6(1):1-8 [20087440.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):235-43 [10712925.001]
  • [Cites] N Engl J Med. 2000 May 4;342(18):1350-8 [10793168.001]
  • [Cites] Bioessays. 2001 Mar;23(3):223-32 [11223879.001]
  • [Cites] Ann Agric Environ Med. 2001;8(1):1-5 [11426918.001]
  • [Cites] Genome Biol. 2001;2(8):REVIEWS3010 [11532220.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1293-300 [11583957.001]
  • [Cites] J Cell Biol. 2002 Jan 21;156(2):299-313 [11790801.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2002 Sep;12(5):373-80 [12198585.001]
  • [Cites] Ann Intern Med. 2002 Oct 1;137(7):603-12 [12353948.001]
  • [Cites] Br Med Bull. 2002;64:1-25 [12421722.001]
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):387-93 [14506738.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1597-604 [15014009.001]
  • [Cites] Exp Oncol. 2004 Jun;26(2):98-105 [15273660.001]
  • [Cites] Hum Mol Genet. 2004 Oct 1;13 Spec No 2:R177-85 [15358723.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 [3056609.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):339-46 [17390374.001]
  • [Cites] J Biol Chem. 2009 Jan 2;284(1):245-53 [19010789.001]
  • [Cites] Mutat Res. 2009 May 31;676(1-2):5-10 [19486858.001]
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):219-25 [19574674.001]
  • [Cites] Saudi J Gastroenterol. 2009 Oct-Dec;15(4):244-52 [19794270.001]
  • [Cites] Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 [19838011.001]
  • [Cites] Indian J Pathol Microbiol. 1990 Apr;33(2):118-23 [2391141.001]
  • (PMID = 20565773.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ PMC2927996
  •  go-up   go-down


59. Stelzer MK, Pitot HC, Liem A, Schweizer J, Mahoney C, Lambert PF: A mouse model for human anal cancer. Cancer Prev Res (Phila); 2010 Dec;3(12):1534-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mouse model for human anal cancer.
  • Human anal cancers are associated with high-risk human papillomaviruses (HPV) that cause other anogenital cancers and head and neck cancers.
  • As with other cancers, HPV16 is the most common high-risk HPV in anal cancers.
  • We describe the generation and characterization of a mouse model for human anal cancer.
  • This model makes use of K14E6 and K14E7 transgenic mice in which the HPV16 E6 and E7 genes are directed in their expression to stratified squamous epithelia.
  • Both E6 and E7 were found to be functionally expressed in the anal epithelia of K14E6/K14E7 transgenic mice.
  • To assess the susceptibility of these mice to anal cancer, mice were treated topically with dimethylbenz[a]anthracene (DMBA), a chemical carcinogen that is known to induce squamous cell carcinomas in other sites.
  • Histopathologic analyses confirmed that the HPV16 transgenic mice were increased in their susceptibility to anal cancers and precancerous lesions.
  • Biomarker analyses demonstrated that these mouse anal cancers exhibit properties that are similar to those observed in HPV-positive precursors to human anal cancer.
  • This is the first mouse model for investigating the contributions of viral and cellular factors in anal carcinogenesis, and should provide a platform for assessing new therapeutic modalities for treating and/or preventing this type of cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Mol Cell Biol. 2003 Dec;23(24):9094-103 [14645521.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4862-71 [12941807.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):263-75 [15137956.001]
  • [Cites] Cancer Res. 1982 Sep;42(9):3519-25 [6286109.001]
  • [Cites] J Pathol. 1990 Jun;161(2):99-103 [2199641.001]
  • [Cites] J Virol. 1996 Mar;70(3):1873-81 [8627712.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Nature. 1998 Nov 5;396(6706):84-8 [9817205.001]
  • [Cites] J Virol. 1999 Jul;73(7):5887-93 [10364340.001]
  • [Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14152-7 [16959885.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1626-35 [17308103.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4605-19 [17510386.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6106-12 [17616666.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2668-73 [17721920.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11585-93 [18089787.001]
  • [Cites] Mol Cancer. 2008;7:3 [18184435.001]
  • [Cites] Ann Intern Med. 2008 Sep 2;149(5):300-6 [18765699.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2375-83 [19189402.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Mod Pathol. 2010 Jan;23(1):144-50 [19838162.001]
  • [Cites] J Am Acad Dermatol. 2010 Sep;63(3):490-8 [20006407.001]
  • [Cites] Br J Dermatol. 2010 Jun;162(6):1269-77 [20184584.001]
  • [Cites] Virology. 2000 Feb 15;267(2):141-50 [10662610.001]
  • [Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8173-80 [14678972.001]
  • (PMID = 20947489.001).
  • [ISSN] 1940-6215
  • [Journal-full-title] Cancer prevention research (Philadelphia, Pa.)
  • [ISO-abbreviation] Cancer Prev Res (Phila)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098428-08; United States / NCI NIH HHS / CA / P01 CA022443-330006; United States / NCI NIH HHS / CA / R01 CA098428-09; United States / NCI NIH HHS / CA / U01 CA141583; United States / NCI NIH HHS / CA / P01 CA022443-320006; United States / NCI NIH HHS / CA / CA098428-08; United States / NCI NIH HHS / CA / CA022443-330006; United States / NCI NIH HHS / CA / CA141583-02; United States / NCI NIH HHS / CA / U01 CA141583-01; United States / NIDCR NIH HHS / DE / R01 DE017315-04; United States / NCI NIH HHS / CA / CA141583-01; United States / NCI NIH HHS / CA / CA022443-320006; United States / NIDCR NIH HHS / DE / R01 DE017315; United States / NIDCR NIH HHS / DE / R01 DE017315-05; United States / NCI NIH HHS / CA / CI T32 CA090217; United States / NCI NIH HHS / CA / T32 CA090217; United States / NCI NIH HHS / CA / U01 CA141583-02; United States / NCI NIH HHS / CA / P01 CA022443; United States / NCI NIH HHS / CA / R01 CA098428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Repressor Proteins; 0 / oncogene protein E7, Human papillomavirus type 16; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  • [Other-IDs] NLM/ NIHMS211621; NLM/ PMC3006089
  •  go-up   go-down


60. Park K, Kim YS, Lee GY, Nam JO, Lee SK, Park RW, Kim SY, Kim IS, Byun Y: Antiangiogenic effect of bile acid acylated heparin derivative. Pharm Res; 2007 Jan;24(1):176-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Endothelial Cells. Extracellular Signal-Regulated MAP Kinases / metabolism. Fibroblast Growth Factors / analysis. Fibroblast Growth Factors / metabolism. Humans. Magnetic Resonance Spectroscopy. Mice. Mice, Inbred C57BL. Microtubules / drug effects. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / pathology. Phosphorylation. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEPARIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Res. 1978 May;12(5):773-82 [566964.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):3000-7 [7686447.001]
  • [Cites] Br J Cancer. 2002 Jun 5;86(11):1803-12 [12087470.001]
  • [Cites] Biochim Biophys Acta. 1985 May 30;845(2):196-203 [3995089.001]
  • [Cites] Pharmacol Rev. 2001 Mar;53(1):93-105 [11171940.001]
  • [Cites] Thromb Res. 1994 Jul 1;75(1):1-32 [8073404.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Sep 15;203(2):1339-47 [7522446.001]
  • [Cites] J Control Release. 2006 Sep 12;114(3):300-6 [16884806.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Br J Cancer. 1984 Apr;49(4):405-13 [6201181.001]
  • [Cites] Langmuir. 2004 Dec 21;20(26):11726-31 [15595804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2193-8 [11854515.001]
  • [Cites] Biochemistry. 1986 Sep 9;25(18):5322-8 [3768351.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4425-31 [7545541.001]
  • [Cites] News Physiol Sci. 2004 Feb;19:16-21 [14739398.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24653-60 [10816596.001]
  • [Cites] Angiogenesis. 1998;2(2):183-99 [14517473.001]
  • [Cites] Thromb Res. 1998 Nov 15;92(4):149-56 [9840023.001]
  • [Cites] Anal Biochem. 1980 Dec;109(2):466-73 [7224172.001]
  • [Cites] Biochemistry. 1994 Apr 5;33(13):3831-40 [8142385.001]
  • [Cites] Thromb Res. 1976 Feb;8(2):195-204 [1251350.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7163-9 [11156426.001]
  • [Cites] Biochemistry. 1994 Aug 30;33(34):10229-48 [7520751.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25902-9 [12704192.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):1029-34 [11069186.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2743-50 [15087389.001]
  • [Cites] Glycobiology. 1996 Apr;6(3):355-66 [8724143.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3722-8 [12097281.001]
  • (PMID = 17109210.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Bile Acids and Salts; 62031-54-3 / Fibroblast Growth Factors; 9005-49-6 / Heparin; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


61. Tsao KC, Wu TL, Chang PY, Hong JH, Wu JT: Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers. J Clin Lab Anal; 2006;20(2):42-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 73,443 asymptomatic individuals were screened on a voluntary basis for cancer at Chang Gung Memorial Hospital in Taiwan using a panel of tumor markers, including alpha fetoprotein (AFP), CA 125, CA 15-3, CA 19-9, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), chromogranin A (CgA), and squamous cell specific antigen (SCC).
  • Of the tumor markers monitored, elevated CA 19-9, CEA, and CA 125 were the most frequently detected in a variety of cancers.
  • Screening with multiple circulating tumor markers provides improved sensitivity for cancer detection in asymptomatic individuals before they reach the fatal advanced stage.
  • [MeSH-major] Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma / diagnosis. Mass Screening / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. CA-19-9 Antigen / analysis. Cohort Studies. Female. Humans. Male. Middle Aged. Sensitivity and Specificity. Sex Distribution. Taiwan / epidemiology


62. El Badry AA, El-Fadle AA, El-Balshy AL: Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma. MedGenMed; 2007;9(3):3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue inhibitor of matrix metalloproteinase-2 in nasopharyngeal carcinoma.
  • The present study was designed to clarify the role of TIMP-2 in nasopharyngeal carcinoma (NPC) patients and to evaluate its importance relative to clinicopathologic parameters.
  • Clinically, in accordance with TNM classification (T: tumor size, N: lymph node involvement, M: distant metastasis), 8 cases were diagnosed as stage II, 12 as stage III, and 10 cases as stage IV; however, pathologic typing with use of the World Health Organization (WHO) classification revealed the presence of 9 specimens of squamous cell carcinoma (WHO type 1), 6 cases of nonkeratinizing carcinoma (WHO type 2), and 15 cases of undifferentiated carcinoma (WHO type 3).
  • In addition, there was a significant positive correlation between TIMP-2 protein positivity and either the clinical staging or the histopathologic typing (P < .01) using Chi-square test (x(2)), suggesting that TIMP-2 can be used as a marker of the severity of NPC.Accordingly, we can assume that TIMP-2 may play a role in regional lymph node and/or distant metastasis and in progression of squamous cell carcinoma.
  • [MeSH-major] Carcinoma / chemistry. Carcinoma / enzymology. Nasopharyngeal Neoplasms / chemistry. Nasopharyngeal Neoplasms / enzymology. Tissue Inhibitor of Metalloproteinase-2 / analysis

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Am J Clin Pathol. 1993 Jan;99(1):18-23 [8422010.001]
  • [Cites] Adv Exp Med Biol. 2000;465:469-83 [10810650.001]
  • [Cites] Br J Cancer. 2000 Jul;83(2):215-8 [10901373.001]
  • [Cites] Hum Pathol. 2000 Aug;31(8):895-904 [10987249.001]
  • [Cites] Int J Oncol. 2000 Dec;17(6):1099-105 [11078794.001]
  • [Cites] Int J Cancer. 2001 Jan 20;95(1):44-50 [11241310.001]
  • [Cites] J Med Invest. 2001 Feb;48(1-2):31-43 [11286015.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):813-20 [11448356.001]
  • [Cites] Int J Colorectal Dis. 2001 Jun;16(3):133-40 [11459286.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3113-9 [11595703.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):26-34 [11796838.001]
  • [Cites] Isr Med Assoc J. 2002 Apr;4(4):247-51 [12001695.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 28;99(11):7414-9 [12032297.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):91-4 [12500407.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] J Biol Chem. 1989 Oct 15;264(29):17374-8 [2793861.001]
  • [Cites] Int J Cancer. 1994 Nov 1;59(3):339-44 [7927938.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Cancer Res. 1996 Apr 1;56(7):1654-9 [8603416.001]
  • [Cites] FEBS Lett. 1996 May 6;385(3):238-40 [8647259.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2707-10 [8665498.001]
  • [Cites] Cancer. 1997 Jan 1;79(1):139-44 [8988738.001]
  • [Cites] Eur J Cell Biol. 1997 Oct;74(2):111-22 [9352216.001]
  • [Cites] Nat Genet. 1997 Dec;17(4):439-44 [9398846.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):650-5 [9484825.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1359-66 [9529029.001]
  • [Cites] Clin Cancer Res. 1997 Sep;3(9):1623-8 [9815852.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):467-73 [9927064.001]
  • [Cites] Anticancer Res. 1999 Mar-Apr;19(2C):1589-92 [10365151.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Head Neck. 1999 Oct;21(7):627-38 [10487950.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16485-90 [1653238.001]
  • [Cites] Anticancer Res. 2000 Mar-Apr;20(2B):1085-91 [10810401.001]
  • (PMID = 18092010.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2
  • [Other-IDs] NLM/ PMC2100075
  •  go-up   go-down


63. Grose R, Fantl V, Werner S, Chioni AM, Jarosz M, Rudling R, Cross B, Hart IR, Dickson C: The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development. EMBO J; 2007 Mar 07;26(5):1268-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.
  • Mice lacking epithelial Fgfr2b show great sensitivity to chemical carcinogenic insult, displaying several oncogenic ha-ras mutations with dramatic development of papillomas and squamous cell carcinomas.
  • Thus we describe a novel role of Fgfr2b and provide the first evidence of a tyrosine kinase receptor playing a tumor suppressive role in the skin.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / chemistry. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Epidermis / metabolism. Epidermis / pathology. Female. Hair / metabolism. Hair / pathology. Hair Follicle / metabolism. Hair Follicle / pathology. Immunohistochemistry. Keratin-5 / genetics. Keratin-5 / metabolism. Male. Mice. Mice, Knockout. Mutation. Papilloma / metabolism. Papilloma / pathology. Sebaceous Glands / metabolism. Sebaceous Glands / pathology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Lett. 2001 Dec 3;79(3):215-9 [11600201.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11336-40 [11562460.001]
  • [Cites] Science. 2002 Apr 26;296(5568):747-9 [11976459.001]
  • [Cites] Development. 2003 Nov;130(21):5241-55 [12954714.001]
  • [Cites] Development. 2003 Nov;130(22):5493-501 [14530295.001]
  • [Cites] Curr Opin Biotechnol. 2003 Oct;14(5):533-7 [14580585.001]
  • [Cites] Oncogene. 1999 Dec 2;18(51):7234-43 [10602477.001]
  • [Cites] Development. 2000 Feb;127(3):483-92 [10631169.001]
  • [Cites] EMBO J. 2000 Aug 1;19(15):3990-4003 [10921880.001]
  • [Cites] Dev Biol. 2001 Mar 1;231(1):47-62 [11180951.001]
  • [Cites] Genome Biol. 2001;2(3):REVIEWS3005 [11276432.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3541-3 [11325814.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8784-90 [14695195.001]
  • [Cites] Eur J Cell Biol. 2004 Feb;83(1):3-11 [15085950.001]
  • [Cites] Genesis. 2004 May;39(1):52-7 [15124227.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1771-8 [15105299.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):236-42 [15368475.001]
  • [Cites] Nature. 2004 Sep 23;431(7007):405-6 [15385993.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Carcinogenesis. 1991 Oct;12(10):1875-81 [1934268.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6896-900 [1379725.001]
  • [Cites] EMBO J. 1993 Mar;12(3):973-86 [7681397.001]
  • [Cites] Science. 1994 Nov 4;266(5186):819-22 [7973639.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):145-54 [7604876.001]
  • [Cites] Genes Dev. 1996 Jan 15;10(2):165-75 [8566750.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):323-30 [9018118.001]
  • [Cites] EMBO J. 1998 Mar 16;17(6):1642-55 [9501086.001]
  • [Cites] Genes Dev. 1998 Oct 15;12(20):3156-61 [9784490.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):138-41 [9916808.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9201-11 [15516981.001]
  • [Cites] Oncogene. 2005 Feb 10;24(7):1290-5 [15592514.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Apr;16(2):179-86 [15863033.001]
  • [Cites] Development. 2005 Jul;132(13):2981-90 [15930103.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):376-82 [16428475.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):651-60 [16329135.001]
  • [Cites] Mol Cell Biol. 2006 May;26(10):3773-84 [16648473.001]
  • [Cites] Science. 2001 Oct 19;294(5542):605-9 [11567106.001]
  • (PMID = 17304214.001).
  • [ISSN] 0261-4189
  • [Journal-full-title] The EMBO journal
  • [ISO-abbreviation] EMBO J.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 076678; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Keratin-5; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 2
  • [Other-IDs] NLM/ PMC1817631; NLM/ UKMS1213
  •  go-up   go-down


64. Lukan N, Ströbel P, Willer A, Kripp M, Dinter D, Mai S, Hochhaus A, Hofheinz RD: Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology; 2009;77(5):293-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
  • BACKGROUND: No standard chemotherapy regimen can be defined for patients with metastatic squamous cell carcinoma of the anus due to the low incidence of this disease and the high cure rate of localized tumors.
  • Anal cancers universally express the epidermal growth factor receptor (EGFR) and KRAS mutations have not been reported in anal cancer thus far.
  • METHODS: We report on 7 patients with metastatic anal cancer treated with cetuximab - a chimeric antibody against EGFR - on a compassionate use basis along with the results of KRAS mutational analysis.
  • CONCLUSION: Cetuximab-based treatment appears to be a valuable treatment option for patients with metastatic KRAS wild-type anal cancer after failure of or as an alternative to cisplatin/5-fluorouracil-based therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Anus Neoplasms / drug therapy. Mutation. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / antagonists & inhibitors. ras Proteins / genetics

  • Genetic Alliance. consumer health - Anal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19923868.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  •  go-up   go-down


65. Hauerstock D, Ennis RD, Grossbard M, Evans A: Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer. Clin Colorectal Cancer; 2010 Oct;9(4):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  • PURPOSE: The purpose of this retrospective study is to determine the results and the toxicity of concurrent chemoradiation for squamous cell carcinoma of the anal canal in HIV-positive patients treated at a single institution.
  • PATIENTS AND METHODS: HIV-positive patients with squamous cell carcinoma of the canal treated at Continuum Cancer Centers-affiliated hospitals were identified from tumor registries.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / complications. Radiotherapy, Conformal


66. Konstantinopoulos PA, Pantanowitz L, Schlecht HP, Dezube BJ: Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus. AIDS Read; 2006 Jun;16(6):301-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Images in HIV/AIDS. HIV-associated squamous cell carcinoma of the anus.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / virology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / virology. HIV Infections / complications


67. Jiménez W, Paszat L, Kupets R, Wilton A, Tinmouth J: Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario. Gynecol Oncol; 2009 Sep;114(3):395-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presumed previous human papillomavirus (HPV) related gynecological cancer in women diagnosed with anal cancer in the province of Ontario.
  • OBJECTIVE: The oncogenic HPV subtypes responsible for gynecologic malignancies have also been implicated in the development of squamous cell cancer of the anus (SCAC).
  • The aim of this study was determine whether women diagnosed with anal cancer are more likely to have a history of HPV-related gynecological cancer as compared to a matched control group.
  • The exposure of interest was previous HPV-related gynecologic cancer, specifically cervical cancer, vulvar cancer and vaginal cancer.
  • Previous HPV-related gynecological cancer (cervical, vaginal or vulvar cancer) was significantly associated with SCAC (OR: 10.5, 95% C.I.: 3.6 to 30.3).
  • The median time between the diagnosis of anal cancer and previous cervical cancer was 20 years.
  • CONCLUSIONS: Previous HPV-related gynecological cancers are strongly associated with anal cancer and may occur decades before the anal cancer.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Genital Neoplasms, Female / epidemiology. Neoplasms, Multiple Primary / epidemiology. Papillomavirus Infections / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19501390.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


68. Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R: Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig Dis Sci; 2008 Mar;53(3):760-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine.
  • Human papilloma virus (HPV) has been found to be a precursor and risk factor for both cervical and anal dysplasia.
  • Cervical dysplasia, which is the precursor to carcinoma, is associated with immunosuppression from a variety of causes; reports of anal dysplasia associated with immune suppression exist as well.
  • We report a case of a 50-year-old woman with refractory ulcerative colitis chronically treated with 6-mercaptopurine that developed severe squamous dysplasia of the rectum.
  • This case highlights the importance of immune suppression in the development of dysplasia of the anus/cervix secondary to HPV infection.
  • [MeSH-major] 6-Mercaptopurine / adverse effects. Colitis, Ulcerative / drug therapy. Immunosuppressive Agents / adverse effects. Neoplasms, Squamous Cell / chemically induced. Rectal Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Transplant Proc. 1973 Mar;5(1):943-7 [4735211.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):61-4 [12085257.001]
  • [Cites] Transplant Proc. 1972 Dec;4(4):719-32 [4345730.001]
  • [Cites] Obstet Gynecol. 1994 Oct;84(4):591-7 [8090399.001]
  • [Cites] J Infect Dis. 1998 Feb;177(2):361-7 [9466522.001]
  • [Cites] Acta Obstet Gynecol Scand. 1978;57(1):73-8 [341640.001]
  • [Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1095-101 [16586444.001]
  • [Cites] Scott Med J. 1980 Oct;25(4):275-7 [7010590.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Surg Oncol. 1995 May;59(1):48-55 [7745978.001]
  • [Cites] Can J Gastroenterol. 2007 Jan;21(1):47-50 [17225882.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1666-9 [8348498.001]
  • [Cites] Gut. 2005 Feb;54(2):237-41 [15647188.001]
  • [Cites] Gastroenterology. 2004 May;126(6):1504-17 [15168363.001]
  • [Cites] Cleve Clin Q. 1985 Summer;52(2):257-61 [4028428.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]
  • [Cites] J Obstet Gynaecol. 2005 Apr;25(3):286-8 [16147738.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Ann Intern Med. 2003 Mar 18;138(6):453-9 [12639077.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):341-6 [11289278.001]
  • [Cites] Am J Epidemiol. 1990 Jun;131(6):945-57; discussion 958-60 [2188500.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):270-80 [15241823.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):940-87 [16530532.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Aug 1;121(2):226-32 [16054967.001]
  • (PMID = 17717741.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; E7WED276I5 / 6-Mercaptopurine
  •  go-up   go-down


69. Martellucci J, Naldini G, Colosimo C, Cionini L, Rossi M: Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy. Surg Endosc; 2009 May;23(5):1054-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of endoanal ultrasound in the follow-up assessment for squamous cell carcinoma of the anal canal treated with radiochemotherapy.
  • BACKGROUND: Radiochemotherapy has largely replaced surgery in the treatment for squamous cell cancer of the anal canal.
  • Transanal ultrasonography is well documented as an important investigation method in the management of anal carcinoma.
  • METHODS: The study enrolled 16 consecutive patients with biopsy-proven squamous carcinoma of the anal canal between 2003 and 2006.
  • CONCLUSIONS: Endoanal ultrasound is a safe and effective method for evaluating and following anal cancer before and after treatment.
  • Experience and evaluation during the period of the ultrasonographic abnormalities could give a clear idea concerning the evolution of the anal tumors treated with radiochemotherapy.
  • [MeSH-major] Anus Neoplasms / diagnostic imaging. Carcinoma, Squamous Cell / diagnostic imaging. Endosonography

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2002 Jul;43(1):77-92 [12098609.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):16-22 [11786758.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):359-64 [10433044.001]
  • [Cites] Surg Clin North Am. 2004 Aug;84(4):1127-49, vii [15261756.001]
  • [Cites] Surg Endosc. 1994 Oct;8(10 ):1186-9 [7809802.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):231-6 [11293755.001]
  • [Cites] Dis Colon Rectum. 2004 Jun;47(6):839-42 [15085443.001]
  • [Cites] Eur J Radiol. 2003 Aug;47(2):142-8 [12880995.001]
  • (PMID = 18813993.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


70. Bendel P, Wittig A, Basilico F, Mauri PL, Sauerwein W: Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001. J Pharm Biomed Anal; 2010 Jan 5;51(1):284-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolism of borono-phenylalanine-fructose complex (BPA-fr) and borocaptate sodium (BSH) in cancer patients--results from EORTC trial 11001.
  • These observations were previously reported for cultured cells and animal models, and are confirmed here in human cancer patients.
  • [MeSH-minor] Animals. Carcinoma, Squamous Cell / therapy. Clinical Trials as Topic. Fructose / chemistry. Head and Neck Neoplasms / therapy. Humans. Magnetic Resonance Spectroscopy / methods. Time Factors

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19735988.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Borohydrides; 0 / Boron Compounds; 0 / Sulfhydryl Compounds; 12294-22-3 / mercaptoundecahydrododecaborate; 30237-26-4 / Fructose; 47E5O17Y3R / Phenylalanine; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


71. Richard SD, Krivak TC, Beriwal S, Zorn KK: Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab.
  • Recurrent vulvar carcinoma with metastasis has few effective treatment options, which are mainly directed toward palliation of symptoms.
  • A 70-year-old woman was originally treated in 1999 for vulvar squamous cell carcinoma (SCC) with radical vulvectomy and bilateral inguinofemoral groin dissection.
  • Despite radical surgical resection with an anal perineal resection, she presented 2 months later with widely metastatic disease.
  • Few treatment options exist for recurrent metastatic vulvar carcinoma.
  • The partial response experienced in our patient suggests its potential use in women with recurrent or metastatic vulvar carcinoma.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021214.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; PQX0D8J21J / Cetuximab; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


72. Arikawa S, Uchida M, Ogoh E, Uozumi J, Yoshida S, Watanabe Y, Kaida H, Ishibashi N, Shirouzu K, Hayabuchi N: [Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal]. Gan To Kagaku Ryoho; 2010 Apr;37(4):727-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal].
  • We report a case of drug eruption (erythema multiforme type) in a 54-year-old woman, following concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal.
  • Although we could not provide sufficient chemotherapy and radiation therapy due to severe side effects, squamous cell carcinoma of the anal canal responded extremely well with a marked decrease in complete response.
  • Concurrent chemoradiotherapy is safe and effective for squamous cell carcinoma of the anal canal, but care is required to prevent drug eruption during treatment.
  • [MeSH-major] Anal Canal / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Carcinoma, Squamous Cell / drug therapy. Erythema Multiforme / chemically induced. Fluorouracil / adverse effects. Mitomycin / therapeutic use. Rectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Erythema Multiforme.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414036.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Steroids; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


73. Yang K, Li Z, Cao Y, Yu X, Mei J: Effect of peptide-conjugated near-infrared fluorescent quantum dots (NIRF-QDs) on the invasion and metastasis of human tongue squamous cell carcinoma cell line Tca8113 in vitro. Int J Mol Sci; 2009 Oct;10(10):4418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of peptide-conjugated near-infrared fluorescent quantum dots (NIRF-QDs) on the invasion and metastasis of human tongue squamous cell carcinoma cell line Tca8113 in vitro.
  • In this study we investigated the effect of near-infrared fluorescent quantum dots (NIRF-QDs, QTracker) on the proliferation, adherence, invasion and chemotaxis of human tongue squamous cell carcinoma cell line Tca8113 in vitro.
  • Cell proliferation and colony formation rate were determined by using a hemocytometer and culture plate.
  • A transwell chamber assay was used to determine the cell invasion, adherence and chemotaxis.
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Movement / drug effects. Cell Proliferation / drug effects. Humans. Spectroscopy, Near-Infrared. Tongue Neoplasms / metabolism. Tongue Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):47-51 [12459736.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Nat Med. 2004 Sep;10(9):993-8 [15334072.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Nat Mater. 2005 Jun;4(6):435-46 [15928695.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11631-8 [16357174.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] Methods Mol Biol. 2007;374:147-59 [17237537.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1138-44 [17283148.001]
  • [Cites] J Am Chem Soc. 2007 Nov 28;129(47):14759-66 [17983227.001]
  • [Cites] BMC Biotechnol. 2007;7:67 [17925032.001]
  • [Cites] Bioconjug Chem. 2008 Feb;19(2):421-7 [18081241.001]
  • [Cites] Langmuir. 2008 Oct 21;24(20):11866-71 [18823093.001]
  • [Cites] Nat Biotechnol. 2001 Jul;19(7):631-5 [11433273.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1759-62 [12459582.001]
  • [Cites] Anal Biochem. 2004 Jan 1;324(1):60-7 [14654046.001]
  • (PMID = 20057952.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptides
  • [Other-IDs] NLM/ PMC2790115
  • [Keywords] NOTNLM ; adherence / chemotaxis / invasion / near-infrared fluorescence / peptide / quantum dots / tumor
  • [General-notes] NLM/ Original DateCompleted: 20100628
  •  go-up   go-down


74. Du Y, Li Z, Li L, Chen ZG, Sun SY, Chen P, Shin DM, Khuri FR, Fu H: Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. J Recept Signal Transduct Res; 2009;29(3-4):182-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
  • Targeting dysregulated signaling pathways in tumors has led to the development of a novel class of signal transduction inhibitors, including inhibitors of the epidermal growth factor (EGF) receptor (EGFR).
  • Here we report the application of a label-free optical biosensor to reveal the rapid response of cancer cells to EGF, expressed as a dynamic mass redistribution (DMR) signal.
  • In response to EGF, squamous cell carcinoma of the head and neck cells exhibited a rapid rise in DMR signal, whereas lung adenocarcinoma cells showed a biphasic DMR profile, suggesting a cell type-dependent DMR response.
  • The assay can also be used for cell-based high-throughput screening of EGF pathway inhibitors, as demonstrated by its robust performance in a 384-well plate format (Z' > 0.5).
  • [MeSH-minor] Antineoplastic Agents / isolation & purification. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Epidermal Growth Factor / pharmacology. Erlotinib Hydrochloride. Humans. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2005 Aug 1;579(19):4175-80 [16038906.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):991-1002 [14967461.001]
  • [Cites] Med Res Rev. 2006 Sep;26(5):569-94 [16788977.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2005;1:666-9 [17282270.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Cancer. 2008 Jul 1;113(1):97-107 [18473353.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25 [16736979.001]
  • [Cites] Nat Rev Cancer. 2002 Jul;2(7):489-501 [12094235.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] J Biomol Screen. 1999;4(2):67-73 [10838414.001]
  • [Cites] Cancer Control. 2007 Jul;14(3):295-304 [17615536.001]
  • [Cites] Oncology (Williston Park). 2006 Feb;20(2):153-61; discussion 162, 166, 169 passim [16562649.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5720-5 [16131087.001]
  • [Cites] Assay Drug Dev Technol. 2006 Oct;4(5):583-95 [17115929.001]
  • [Cites] Eur J Cancer. 2007 Jan;43(1):35-45 [17098420.001]
  • [Cites] Cancer Res. 1996 Aug 1;56(15):3540-5 [8758924.001]
  • [Cites] Biophys J. 2006 Sep 1;91(5):1925-40 [16766609.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2004;44:195-217 [14744244.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Biol Chem. 1988 Mar 5;263(7):3496-500 [2830286.001]
  • [Cites] Annu Rev Biochem. 1998;67:481-507 [9759495.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Biotechnol J. 2008 Apr;3(4):484-95 [18412175.001]
  • [Cites] Clin Lung Cancer. 2007 Feb;8 Suppl 2:S79-85 [17382029.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 2):4249s-4253s [15217968.001]
  • [Cites] Oncol Rep. 2008 Jan;19(1):65-71 [18097577.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2008 Fall;20(3):217-23 [19038731.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] ScientificWorldJournal. 2008;8:909-19 [18836658.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 3;90(11):824-32 [9625170.001]
  • (PMID = 19604037.001).
  • [ISSN] 1532-4281
  • [Journal-full-title] Journal of receptor and signal transduction research
  • [ISO-abbreviation] J. Recept. Signal Transduct. Res.
  • [Language] eng
  • [Grant] United States / NHGRI NIH HHS / HG / U54 HG003918; United States / NCI NIH HHS / CA / 5 P50 CA128613; United States / NCI NIH HHS / CA / P01 CA116676-04; United States / NHGRI NIH HHS / HG / 5U54 HG003918; United States / NHGRI NIH HHS / HG / U54 HG003918-03; United States / NCI NIH HHS / CA / P01 CA116676; United States / NCI NIH HHS / CA / T32 CA160040; United States / NCI NIH HHS / CA / P50 CA128613-03; United States / NCI NIH HHS / CA / P50 CA128613
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS142951; NLM/ PMC3746742
  •  go-up   go-down


75. Mäusbacher N, Schreiber TB, Daub H: Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulation. Mol Cell Proteomics; 2010 Nov;9(11):2337-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glycoprotein capture and quantitative phosphoproteomics indicate coordinated regulation of cell migration upon lysophosphatidic acid stimulation.
  • The underlying signaling mechanisms are still incompletely understood, including those that operate at the plasma membrane to modulate cell-cell and cell-matrix interactions in LPA-promoted cell migration.
  • To explore LPA-evoked phosphoregulation with a focus on cell surface proteins, we combined glycoproteome enrichment by immobilized lectins with SILAC-based quantitative phosphoproteomics.
  • We performed biological replicate analyses in SCC-9 squamous cell carcinoma cells and repeatedly quantified the effect of 1.5- and 5-min LPA treatment on more than 700 distinct phosphorylations in lectin-purified proteins.
  • We detected many regulated phosphorylation events on various types of plasma membrane proteins such as cell adhesion molecules constituting adherens junctions, desmosomes, and hemidesmosomes.
  • Several of these LPA-regulated phosphorylation sites have been characterized in a biological context other than G protein-coupled receptor signaling, and the transfer of this functional information suggests coordinated and multifactorial cell adhesion control in LPA-induced cell migration.
  • Additionally, we identified LPA-mediated activation loop phosphorylation of the serine/threonine kinase Wnk1 and verified a role of Wnk1 for LPA-induced cell migration in knock-down experiments.
  • In conclusion, the glycoproteome phosphoproteomics strategy described here sheds light on incompletely understood mechanisms in LPA-induced cell migratory behavior.
  • [MeSH-major] Cell Movement / drug effects. Glycoproteins / chemistry. Lysophospholipids / pharmacology. Phosphoproteins / chemistry. Proteomics / methods
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line, Tumor. Computational Biology. Humans. Molecular Sequence Data. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Receptors, G-Protein-Coupled / metabolism. Receptors, Lysophosphatidic Acid / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23038-44 [15039423.001]
  • [Cites] Anal Chem. 2004 Jul 1;76(13):3590-8 [15228329.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):3935-43 [15253627.001]
  • [Cites] J Cell Biochem. 2004 Aug 1;92(5):949-66 [15258918.001]
  • [Cites] Mol Cell. 2004 Sep 24;15(6):937-49 [15383283.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Biol Chem. 1990 Aug 5;265(22):12820-7 [2115882.001]
  • [Cites] J Biol Chem. 1991 May 5;266(13):8355-62 [2022651.001]
  • [Cites] J Biol Chem. 1992 Apr 25;267(12):8672-8 [1314835.001]
  • [Cites] Cell. 1992 Aug 7;70(3):389-99 [1643657.001]
  • [Cites] J Cell Physiol. 1994 Jan;158(1):151-9 [7505275.001]
  • [Cites] EMBO J. 1997 Dec 1;16(23):7032-44 [9384582.001]
  • [Cites] Science. 1998 Jun 26;280(5372):2112-4 [9641916.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1281-4 [9812885.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1279-80 [9867633.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):471-8 [10024525.001]
  • [Cites] J Biol Chem. 1999 Jul 16;274(29):20206-14 [10400637.001]
  • [Cites] Thromb Haemost. 2005 Jan;93(1):27-34 [15630487.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2218-28 [15688026.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):873-86 [15858219.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26653-8 [15883153.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1391-8 [16273072.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D412-6 [18940858.001]
  • [Cites] Proteomics. 2008 Dec;8(23-24):5108-18 [19016532.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16795-801 [10828064.001]
  • [Cites] Mol Biol Cell. 2001 Feb;12(2):351-65 [11179420.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):7108-13 [11383510.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2375-87 [11884620.001]
  • [Cites] J Biol Chem. 2002 Apr 12;277(15):12838-45 [11823465.001]
  • [Cites] Mol Biol Cell. 2002 Jun;13(6):2031-44 [12058067.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29431-6 [12058027.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6329-36 [12414665.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48456-62 [12374799.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] EMBO J. 2003 May 15;22(10):2411-21 [12743035.001]
  • [Cites] Biochemistry. 2003 Aug 5;42(30):9195-204 [12885254.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] J Biol Chem. 2005 Dec 30;280(52):42685-93 [16263722.001]
  • [Cites] Mol Cell Proteomics. 2006 Feb;5(2):226-33 [16263699.001]
  • [Cites] Mol Cell Proteomics. 2006 May;5(5):923-34 [16452088.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(14):5481-96 [16809781.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Immunity. 2009 Jan 16;30(1):143-54 [19144319.001]
  • [Cites] Mol Cell Proteomics. 2009 Feb;8(2):287-301 [18923192.001]
  • [Cites] Cell. 2009 Aug 7;138(3):525-36 [19665974.001]
  • [Cites] Curr Opin Chem Biol. 2009 Oct;13(4):414-20 [19620020.001]
  • [Cites] Science. 2009 Sep 25;325(5948):1682-6 [19779198.001]
  • [Cites] Mol Cell. 2010 Feb 26;37(4):551-66 [20188673.001]
  • [Cites] Nat Rev Mol Cell Biol. 2010 Jun;11(6):427-39 [20461098.001]
  • [Cites] Mol Cell Proteomics. 2010 Jun;9(6):1047-62 [20071362.001]
  • [Cites] Cell. 2006 Nov 3;127(3):635-48 [17081983.001]
  • [Cites] J Neurochem. 2006 Nov;99(4):1114-21 [17018027.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7381-90 [16785992.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7401-10 [16785995.001]
  • [Cites] J Cell Biol. 2007 Jan 1;176(1):89-100 [17190791.001]
  • [Cites] Nat Biotechnol. 2007 Mar;25(3):285-6 [17344875.001]
  • [Cites] Nat Protoc. 2006;1(6):2856-60 [17406544.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11221-9 [17287208.001]
  • [Cites] Methods Mol Biol. 2007;359:37-52 [17484109.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Jul;16(4):365-72 [17565280.001]
  • [Cites] Anal Chem. 2007 Aug 1;79(15):5826-37 [17591751.001]
  • [Cites] Nat Protoc. 2007;2(8):1896-906 [17703201.001]
  • [Cites] Proteomics. 2007 Aug;7(16):2751-68 [17703509.001]
  • [Cites] Mol Biol Cell. 2007 Sep;18(9):3512-22 [17615294.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Semin Cancer Biol. 2008 Feb;18(1):65-76 [18023204.001]
  • [Cites] Cancer Immunol Immunother. 2008 Sep;57(9):1347-55 [18297283.001]
  • [Cites] Methods Mol Biol. 2008;484:263-76 [18592185.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3304-13 [18578522.001]
  • [Cites] Mol Cell. 2008 Aug 8;31(3):438-48 [18691976.001]
  • [Cites] Curr Opin Cell Biol. 2008 Oct;20(5):589-96 [18583123.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1763-77 [18515860.001]
  • [Cites] J Cell Sci. 2008 Oct 15;121(Pt 20):3293-304 [18843116.001]
  • [Cites] Nat Biotechnol. 2008 Dec;26(12):1367-72 [19029910.001]
  • (PMID = 20639409.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Lysophospholipids; 0 / Phosphoproteins; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2984229
  •  go-up   go-down


76. Sato E, Fujimoto J, Toyoki H, Sakaguchi H, Alam SM, Jahan I, Tamaya T: Expression of IP-10 related to angiogenesis in uterine cervical cancers. Br J Cancer; 2007 Jun 4;96(11):1735-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Chemokines, CXC / genetics. Neovascularization, Pathologic / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Cancer Res. 1985;43:175-203 [2581424.001]
  • [Cites] Cancer. 1982 Sep 1;50(5):932-8 [6807530.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 5;210(1):51-7 [7537965.001]
  • [Cites] Blood. 1996 May 1;87(9):3877-82 [8611715.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):884-8 [8611421.001]
  • [Cites] Invasion Metastasis. 1995;15(5-6):203-10 [8765195.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6 [8943014.001]
  • [Cites] Cancer Lett. 1997 Jan 1;111(1-2):21-6 [9022124.001]
  • [Cites] Cancer Res. 2000 May 15;60(10):2632-5 [10825134.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3662-5 [10910083.001]
  • [Cites] Cancer Immunol Immunother. 2001 Jan;49(11):587-92 [11225989.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):313-6 [11487257.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):149-53 [11948506.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):430-4 [11996475.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Immunol. 1997 Aug 1;159(3):1437-43 [9233641.001]
  • [Cites] Blood. 1997 Aug 1;90(3):909-28 [9242519.001]
  • [Cites] Eur J Gynaecol Oncol. 1997;18(5):349-52 [9378151.001]
  • [Cites] Cancer Lett. 1998 Apr 10;126(1):83-8 [9563652.001]
  • [Cites] Cancer Lett. 1998 Aug 14;130(1-2):115-20 [9751263.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2528-33 [9874459.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1249-54 [10098767.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):827-33 [10360662.001]
  • [Cites] Cancer Lett. 1998 Dec 11;134(1):15-22 [10381125.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3041-4 [10397240.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2721-9 [16081850.001]
  • [Cites] J Immunol. 2006 Mar 1;176(5):3098-107 [16493069.001]
  • [Cites] Circ Res. 2006 Mar 17;98(5):617-25 [16484616.001]
  • [Cites] Exp Eye Res. 2006 Aug;83(2):374-9 [16674942.001]
  • [Cites] Ann Oncol. 2002 Oct;13(10):1598-604 [12377648.001]
  • [Cites] J Exp Med. 2003 Jun 2;197(11):1537-49 [12782716.001]
  • [Cites] Am J Reprod Immunol. 2003 Jul;50(1):60-5 [14506929.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):466-9 [15226772.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • (PMID = 17505511.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL10 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines, CXC; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2359925
  •  go-up   go-down


77. Scarpini C, White V, Muralidhar B, Patterson A, Hickey N, Singh N, Mullerat J, Winslet M, Davies RJ, Phillips ML, Stacey P, Laskey RA, Miller R, Nathan M, Coleman N: Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2855-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved screening for anal neoplasia by immunocytochemical detection of minichromosome maintenance proteins.
  • PURPOSE: Early detection of anal intraepithelial neoplasia (AIN) and anal squamous cell carcinoma (SCC) by screening will improve clinical outcome.
  • Assessment of anal cytology samples using routine Papanicolaou testing suffers from shortcomings in sensitivity and/or specificity, suggesting that screening tests based on biomarkers may be of value.
  • We tested the suitability in this context of minichromosome maintenance (MCM) proteins, accurate markers of the deregulated cell cycle entry that characterizes malignancy and premalignancy.
  • EXPERIMENTAL DESIGN: We undertook an initial immunohistochemical study of 54 anal tissue samples and validated our findings using an independent prospective cohort study of 235 anal cytology samples from 144 subjects.
  • RESULTS: In the progression from normal anal epithelium through AIN to SCC, there was increasing expression of MCM2 and MCM5, including in the superficial epithelial third, the source of the majority of cells collected by anal swab.
  • MCM LIs in the superficial layers were significantly greater than LIs for Ki67, an alternative marker of cell cycle entry (P<0.0001).
  • By immunocytochemistry using a mixture of anti-MCM2 and anti-MCM5 antibodies, immunopositive cells were readily identified in anal cytology samples, even at low magnification.
  • CONCLUSIONS: MCMs are promising biomarkers for improving detection of AIN and SCC in anal cytology samples.
  • [MeSH-major] Anus Neoplasms / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cell Cycle Proteins / metabolism. Nuclear Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18843031.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105359875; United Kingdom / Medical Research Council / / MC/ U105359878; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Ki-67 Antigen; 0 / MCM5 protein, human; 0 / Nuclear Proteins; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2
  •  go-up   go-down


78. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, Sidransky D: ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle; 2008 Sep 15;7(18):2846-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATM kinase is a master switch for the Delta Np63 alpha phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):305-11 [17224650.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):300-4 [17264676.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):274-85 [17264681.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):240-5 [17297296.001]
  • [Cites] Cell Cycle. 2007 Feb 1;6(3):246-54 [17297308.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):931-42 [17457059.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1370-80 [17446929.001]
  • [Cites] Cell Cycle. 2007 May 2;6(9):1062-71 [17426453.001]
  • [Cites] Cell Cycle. 2006 Nov 1;5(21):2489-94 [17106255.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6325-32 [17616691.001]
  • [Cites] Cell Cycle. 2007 Aug 1;6(15):1831-6 [17671427.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3224-33 [10757806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5462-7 [10805802.001]
  • [Cites] Oncogene. 2000 Jun 22;19(27):3126-30 [10871867.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):22719-27 [10801797.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4016-20 [10945600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1817-22 [11172034.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):375-8 [11283598.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1803-15 [11313928.001]
  • [Cites] Eur J Biochem. 2001 May;268(10):2764-72 [11358490.001]
  • [Cites] Mol Pharmacol. 2001 Sep;60(3):405-15 [11502869.001]
  • [Cites] Apoptosis. 2007 Oct;12(10):1847-55 [17636382.001]
  • [Cites] Cell Cycle. 2007 Oct 1;6(19):2339-40 [17914283.001]
  • [Cites] Cell Cycle. 2007 Dec 15;6(24):3114-31 [18075315.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell Cycle. 2008 May 1;7(9):1231-7 [18418053.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1353-9 [18418074.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):80-9 [14657672.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51408-14 [14555649.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1829-37 [14647429.001]
  • [Cites] Annu Rev Biochem. 2004;73:39-85 [15189136.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] Methods Enzymol. 1991;200:3-37 [1835513.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21396-403 [7545671.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):518-26 [9030780.001]
  • [Cites] Eur J Biochem. 1997 Jan 15;243(1-2):527-36 [9030781.001]
  • [Cites] Science. 1998 Sep 11;281(5383):1674-7 [9733514.001]
  • [Cites] Mol Cell. 1998 Sep;2(3):305-16 [9774969.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2781-6 [10383130.001]
  • [Cites] J Virol. 2004 Dec;78(24):13501-11 [15564461.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9152-9 [15604286.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1285-95 [15467455.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1099-105 [10594758.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37538-43 [10608806.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7803-10 [10713094.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31819-24 [11431470.001]
  • [Cites] Curr Opin Chem Biol. 2001 Oct;5(5):591-602 [11578935.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):41717-24 [11546792.001]
  • [Cites] Nat Biotechnol. 2002 Mar;20(3):301-5 [11875433.001]
  • [Cites] Nature. 2002 Apr 4;416(6880):560-4 [11932750.001]
  • [Cites] Exp Cell Res. 2002 Jun 10;276(2):194-200 [12027449.001]
  • [Cites] Cancer Cell. 2002 May;1(4):369-79 [12086851.001]
  • [Cites] Neoplasia. 2002 Sep-Oct;4(5):400-8 [12192598.001]
  • [Cites] Cell Cycle. 2002 May-Jun;1(3):162-8 [12429926.001]
  • [Cites] Anal Chem. 2002 Nov 1;74(21):5593-9 [12433093.001]
  • [Cites] Mol Cell Biol. 2003 Apr;23(7):2264-76 [12640112.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12207-13 [12519769.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2351-7 [12750249.001]
  • [Cites] Laryngoscope. 2003 Jun;113(6):936-9 [12782800.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3635-44 [12789272.001]
  • [Cites] Prog Cell Cycle Res. 2003;5:235-48 [14593718.001]
  • [Cites] Cell Cycle. 2004 Nov;3(11):1358-62 [15492512.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):758-66 [15705872.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5056-61 [15788536.001]
  • [Cites] Nat Cell Biol. 2005 May;7(5):493-500 [15834407.001]
  • [Cites] Cell Cycle. 2005 May;4(5):710-6 [15846104.001]
  • [Cites] J Biol Chem. 2005 Jul 8;280(27):25485-90 [15899889.001]
  • [Cites] EMBO J. 2005 Jul 6;24(13):2458-71 [15944736.001]
  • [Cites] Mol Cancer. 2005;4(1):25 [16033649.001]
  • [Cites] Oncogene. 2005 Oct 20;24(46):6970-5 [16007154.001]
  • [Cites] Int J Mol Med. 2005 Dec;16(6):1065-70 [16273287.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1313-5 [16123597.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1440-7 [16177572.001]
  • [Cites] Neuron. 2005 Dec 8;48(5):743-56 [16337913.001]
  • [Cites] Nat Cell Biol. 2006 Jan;8(1):37-45 [16327781.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):1-2 [16413463.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):45-56 [16413471.001]
  • [Cites] Methods Enzymol. 2005;405:82-115 [16413312.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):38-44 [16359856.001]
  • [Cites] Cell Cycle. 2006 Jun;5(12):1342-7 [16760655.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1390-6 [16885742.001]
  • [Cites] Laryngoscope. 2006 Aug;116(8):1409-16 [16885745.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7870-9 [16912160.001]
  • [Cites] Development. 2006 Dec;133(23):4783-92 [17079275.001]
  • (PMID = 18769144.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / DE013561-08; United States / NIDCR NIH HHS / DE / R01 DE013561; United States / NIDCR NIH HHS / DE / R01 DE013561-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Protein Kinase Inhibitors; 0 / RNA, Small Interfering; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 1114-81-4 / Phosphothreonine; 17885-08-4 / Phosphoserine; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS280819; NLM/ PMC3069617
  •  go-up   go-down


79. Eng C: Anal cancer: current and future methodology. Cancer Invest; 2006 Aug-Sep;24(5):535-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer: current and future methodology.
  • Despite the small number of patients affected by carcinoma of the anal canal it remains one of the most challenging cancers to treat.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Anus Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Carcinoma in Situ / drug therapy. Carcinoma in Situ / pathology. Carcinoma in Situ / radiotherapy. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Cisplatin / therapeutic use. Clinical Trials as Topic. Fluorouracil / therapeutic use. HIV Infections / complications. Humans. Mitomycin / therapeutic use. Neoadjuvant Therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm, Residual. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939964.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 64
  •  go-up   go-down


80. Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch, Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch; 2005 Apr;446(4):421-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the expression of ADAM15 and its potential ligand, integrin alpha(v)beta3 (CD51/CD61), in lung carcinoma cell lines and tissues.
  • Most small cell lung carcinomas (SCLCs) and non-SCLC cell lines were ADAM15, alpha(v) and beta3 integrin mRNA positive.
  • Half of the cell lines expressed ADAM15, and three expressed the alpha(v)beta3 heterodimer at the cell surface as shown using flow cytometry.
  • Paraffin sections of pulmonary epithelial tumors, including SCLCs (n=26), squamous cell cancer (SCCs, n=27) and adenocarcinomas (ACs, n=17) were stained with antibodies to the ectosolic and cytosolic domain of ADAM15 and alpha(v)beta3 integrin complex.
  • In summary, lung carcinoma cell lines and tissues were frequently ADAM15 positive.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Integrin alphaVbeta3 / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Metalloendopeptidases / metabolism
  • [MeSH-minor] ADAM Proteins. Aged. Cell Line, Tumor. Female. Flow Cytometry. Humans. Lung / cytology. Lung / metabolism. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / metabolism. RNA, Neoplasm / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 18;235(2):437-42 [9199213.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1033-8 [10514384.001]
  • [Cites] J Cell Sci. 1999 Feb;112 ( Pt 4):579-87 [9914169.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33683-9 [12091380.001]
  • [Cites] Differentiation. 1988;37(2):158-71 [2840315.001]
  • [Cites] Haematologica. 2002 Aug;87(8):836-45 [12161360.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):598-606 [14519395.001]
  • [Cites] Pathol Res Pract. 1998;194(10):701-4 [9820866.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2062-9 [15026344.001]
  • [Cites] J Biol Chem. 1998 Oct 2;273(40):26236-47 [9748307.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):34922-30 [10944520.001]
  • [Cites] J Biol Chem. 1996 Mar 1;271(9):4593-6 [8617717.001]
  • [Cites] Thromb Haemost. 2003 Apr;89(4):622-31 [12669115.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1323-32 [8794871.001]
  • [Cites] Cell. 1996 May 31;85(5):683-93 [8646777.001]
  • [Cites] Mol Cell Biol. 2003 Aug;23(16):5614-24 [12897135.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] Mol Immunol. 1987 Jul;24(7):699-705 [3309626.001]
  • [Cites] Trends Cell Biol. 1994 Jul;4(7):256-61 [14731666.001]
  • [Cites] Eur Respir J. 1998 Feb;11(2):400-7 [9551745.001]
  • [Cites] Clin Exp Metastasis. 2002;19(8):717-25 [12553378.001]
  • [Cites] J Biol Chem. 2002 May 17;277(20):17804-10 [11882657.001]
  • [Cites] Neoplasia. 2002 May-Jun;4(3):191-4 [11988838.001]
  • [Cites] Oncol Res. 1993;5(10-11):441-51 [8054705.001]
  • [Cites] Pathobiology. 2004;71(4):185-92 [15263807.001]
  • [Cites] Biochem Soc Trans. 1999 Feb;27(2):255-9 [10093743.001]
  • [Cites] Anal Biochem. 1984 Feb;136(2):458-64 [6721145.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):1129-41 [11891209.001]
  • [Cites] Pathol Int. 1995 Jul;45(7):493-500 [7551009.001]
  • [Cites] J Cell Biol. 2004 Mar 15;164(6):935-41 [15024036.001]
  • [Cites] Arthritis Rheum. 1999 Sep;42(9):1946-50 [10513811.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2046-54 [11592366.001]
  • [Cites] Hum Pathol. 1997 Sep;28(9):1018-25 [9308725.001]
  • [Cites] J Comp Neurol. 2003 Oct 6;465(1):1-10 [12926012.001]
  • [Cites] J Biol Chem. 1998 Mar 27;273(13):7345-50 [9516430.001]
  • [Cites] Int J Cancer. 1976 Jan 15;17(1):62-70 [175022.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1613-7 [11696421.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1209-14 [14973118.001]
  • [Cites] Am J Pathol. 1998 Nov;153(5):1347-51 [9811323.001]
  • [Cites] Cancer Res. 1997 Apr 15;57(8):1554-60 [9108459.001]
  • [Cites] Jpn J Cancer Res. 1996 May;87(5):451-8 [8641981.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15490-7 [10809781.001]
  • [Cites] Genes Dev. 2003 Jan 1;17(1):7-30 [12514095.001]
  • [Cites] Exp Cell Res. 2001 Nov 15;271(1):152-60 [11697891.001]
  • [Cites] J Cell Biol. 1995 Oct;131(2):275-8 [7593158.001]
  • [Cites] J Exp Med. 1999 Jan 4;189(1):169-78 [9874573.001]
  • [Cites] FASEB J. 1997 Feb;11(2):173-80 [9039960.001]
  • [Cites] J Cancer Res Clin Oncol. 1980 Jan;96(1):27-33 [7358770.001]
  • (PMID = 15756594.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Integrin alphaVbeta3; 0 / Membrane Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM15 protein, human; EC 3.4.24.- / Metalloendopeptidases
  •  go-up   go-down


81. Hatzaras I, Abir F, Kozol R, Sullivan P, Longo WE: The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000. Conn Med; 2005 May;69(5):261-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The demographics, histopathology and patterns of treatment of anal cancer in Connecticut: 1980-2000.
  • OBJECTIVES: Examine the epidemiology and clinical characteristics of anal cancer in the State of Connecticut.
  • RESULTS: A total of 646 anal cancers (410 females, 236 males) were diagnosed (mean age: 63.4 years).
  • The most prominent histological type was squamous cell carcinoma, followed by adenocarcinoma and cloacogenic carcinoma.
  • CONCLUSIONS: Anal cancer incidence in Connecticut increased in the 21-year period 1980 to 2000, affecting the rate for African-American men more than other race-specific and gender-specific population subgroups.
  • Anal cancer affects women more often than men.
  • Squamous cell carcinoma is the most common histological type.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anus Neoplasms / epidemiology. Anus Neoplasms / pathology. Carcinoma, Squamous Cell / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16114640.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Badin S, Iqbal A, Sikder M, Chang VT: Persistent pain in anal cancer survivors. J Cancer Surviv; 2008 Jun;2(2):79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent pain in anal cancer survivors.
  • RESULTS: Two patients presented with painful anal lesions that were diagnosed as squamous cell carcinoma of the anus.
  • Despite successful treatment with chemotherapy and radiation, their pain syndromes worsened after treatment with development of a lumbosacral plexopathy that required regular followup, imaging, and pain medications.
  • IMPLICATIONS FOR CANCER SURVIVORS: Treatment related lumbosacral plexopathy may be an unrecognized consequence of the successful treatment of anal carcinoma.
  • [MeSH-major] Anus Neoplasms / complications. Pain / epidemiology. Postoperative Complications / epidemiology. Survivors

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurology. 1985 Jan;35(1):1-7 [2981416.001]
  • [Cites] CA Cancer J Clin. 2003 May-Jun;53(3):172-96 [12809410.001]
  • [Cites] Mayo Clin Proc. 1997 Sep;72 (9):823-9 [9294528.001]
  • [Cites] Clin Radiol. 2006 Dec;61(12 ):987-95 [17097418.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3283-90 [10506631.001]
  • [Cites] Am Fam Physician. 2005 Feb 15;71(4):699-706 [15742907.001]
  • [Cites] Arch Neurol. 2003 Nov;60(11):1524-34 [14623723.001]
  • [Cites] Neurology. 1985 Jan;35(1):8-15 [2981417.001]
  • [Cites] Electromyogr Clin Neurophysiol. 1990 Aug-Sep;30(5):277-82 [2226271.001]
  • [Cites] Radiother Oncol. 1996 Feb;38(2):121-30 [8966224.001]
  • [Cites] Clin J Pain. 2002 Mar-Apr;18(2):75-6 [11882769.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2006 Jun;18(5):427-8 [16817337.001]
  • [Cites] Semin Neurol. 2004 Dec;24(4):385-93 [15637650.001]
  • [Cites] Neurol Clin. 1989 May;7(2):333-60 [2657380.001]
  • [Cites] Radiother Oncol. 2001 Mar;58(3):279-86 [11230889.001]
  • [Cites] J Pain Symptom Manage. 2002 Dec;24(6):578-85 [12551807.001]
  • (PMID = 18648976.001).
  • [ISSN] 1932-2267
  • [Journal-full-title] Journal of cancer survivorship : research and practice
  • [ISO-abbreviation] J Cancer Surviv
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J: Cancers attributable to human papillomavirus infection. Sex Health; 2010 Sep;7(3):244-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the human papillomavirus (HPV) vaccine was introduced primarily as a cervical cancer prevention vaccine, HPV has a causal role in several types of cancer.
  • This article reviews the epidemiological evidence for the role of HPV in human cancer, and describes Australian trends in these cancers.
  • HPV is a necessary cause of cervical cancer.
  • The currently vaccine-preventable subtypes of HPV 16 and 18 are responsible for ~70% of cervical cancer.
  • The prevalence of HPV in penile cancer is ~50% and incidence has not recently changed.
  • For anal cancer, ~85% of cases are HPV positive, and incidence has increased significantly in both men and women over the past 20 years.
  • Overall, 1154 HPV-related cancer cases were potentially preventable by vaccination.
  • If HPV-related cancers at non-cervical sites are prevented by vaccination, then a similar number of cancer cases will be prevented as in the cervix.
  • However, almost one-quarter of the potentially preventable cancer cases are in men, who are not included in the current national immunisation program.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cervical Intraepithelial Neoplasia / epidemiology. Cross-Cultural Comparison. Human papillomavirus 16. Human papillomavirus 18. Oropharyngeal Neoplasms / epidemiology. Papillomavirus Infections / epidemiology. Penile Neoplasms / epidemiology. Sexually Transmitted Diseases, Viral / epidemiology. Uterine Cervical Neoplasms / epidemiology


84. Pineda CE, Berry JM, Jay N, Palefsky JM, Welton ML: High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience. Dis Colon Rectum; 2008 Jun;51(6):829-35; discussion 835-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution anoscopy targeted surgical destruction of anal high-grade squamous intraepithelial lesions: a ten-year experience.
  • PURPOSE: This study was designed to determine whether high-resolution anoscopy and targeted surgical destruction of anal high-grade squamous intraepithelial lesions is effective in controlling high-grade squamous intraepithelial lesions while preserving normal tissues.
  • METHODS: Retrospective review of 246 patients with high-grade squamous intraepithelial lesions treated with high-resolution anoscopy-targeted surgical destruction from 1996 to 2006, with at least one follow-up at a minimum two months with physical examination, high-resolution anoscopy, cytology, and biopsy when indicated.
  • Recurrent high-grade squamous intraepithelial lesions occurred in 114 patients (57 percent) at an average 19 (range, 3-92) months; 26 of these required surgery.
  • Despite treatment, three patients progressed to invasive cancer (1.2 percent).
  • At their last visit, 192 patients (78 percent) had no evidence of high-grade squamous intraepithelial lesions.
  • CONCLUSIONS: High-resolution anoscopy-targeted destruction combined with office-based surveillance and therapy is effective in controlling high-grade squamous intraepithelial lesions and is superior to reports of expectant management or traditional mapping procedures.
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Proctoscopy

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18363070.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Sato H, Maeda K, Koide Y, Matsuoka H, Noro T, Honda K, Shiota M, Endo T, Ozeki S, Fukuda M: [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2647-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Four cases of anal squamous cell carcinoma treated by chemoradiotherapy].
  • We reviewed clinical records of 4 cases with squamous cell carcinoma in anus to evaluate the clinical effectiveness of the chemoradiotherapy.
  • On the first day of radiation therapy, 750 mg/m2 of 5-FU in the form of a continuous 24-hour infusion for 5 days was given.
  • All patients had complete response in the anal lesion after chemoradiotherapy.
  • No patients had any sign of recurrence in anal lesion.
  • Chemoradiotherapy was expected to be a safe and effective treatment to improve prognosis for anal squamous carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224667.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Hofman JW, Carstens MG, van Zeeland F, Helwig C, Flesch FM, Hennink WE, van Nostrum CF: Photocytotoxicity of mTHPC (temoporfin) loaded polymeric micelles mediated by lipase catalyzed degradation. Pharm Res; 2008 Sep;25(9):2065-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cellular uptake of the loaded micelles, and their photocytotoxicity on human neck squamous carcinoma cells in the absence and presence of lipase were compared with free and liposomal mTHPC (Fospeg).
  • [MeSH-minor] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. Cell Survival / drug effects. Chemistry, Pharmaceutical. Dose-Response Relationship, Drug. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. Humans. Liposomes. Technology, Pharmaceutical / methods

  • Hazardous Substances Data Bank. CAPROLACTONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):889-905 [9637138.001]
  • [Cites] Int J Cancer. 1994 Jun 15;57(6):883-8 [8206681.001]
  • [Cites] Eur J Pharm Biopharm. 1999 Sep;48(2):101-11 [10469928.001]
  • [Cites] J Drug Target. 2004 Jul;12(6):373-84 [15545087.001]
  • [Cites] Biomacromolecules. 2005 Sep-Oct;6(5):2541-54 [16153091.001]
  • [Cites] Biochim Biophys Acta. 2005 Oct 10;1725(3):394-402 [16051442.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7538-44 [16243829.001]
  • [Cites] J Control Release. 2005 Dec 5;109(1-3):169-88 [16289422.001]
  • [Cites] Int J Pharm. 2006 Feb 3;308(1-2):183-9 [16324807.001]
  • [Cites] Eur J Pharm Sci. 2006 May;28(1-2):134-40 [16504490.001]
  • [Cites] Biomaterials. 2006 Aug;27(24):4356-73 [16650890.001]
  • [Cites] J Photochem Photobiol B. 2006 Jul 3;84(1):56-63 [16520059.001]
  • [Cites] Lasers Surg Med. 2006 Jun;38(5):356-63 [16392142.001]
  • [Cites] Eur J Pharm Biopharm. 2006 Nov;64(3):261-8 [16884896.001]
  • [Cites] Pharm Res. 2007 Jan;24(1):1-16 [17109211.001]
  • [Cites] J Control Release. 2006 Nov 28;116(2):139-49 [16926059.001]
  • [Cites] Photochem Photobiol Sci. 2007 Jun;6(6):619-27 [17549263.001]
  • [Cites] Exp Lung Res. 2007 Jun-Jul;33(5):217-25 [17620184.001]
  • [Cites] J Control Release. 2007 Jul 31;120(3):131-48 [17582642.001]
  • [Cites] J Control Release. 2007 Dec 20;124(3):144-53 [17936395.001]
  • [Cites] J Pharm Sci. 2008 Jan;97(1):506-18 [17879976.001]
  • [Cites] Eur J Pharm Biopharm. 2008 Mar;68(3):596-606 [17949956.001]
  • [Cites] J Pharm Sci. 2000 Jan;89(1):52-62 [10664538.001]
  • [Cites] J Control Release. 2001 Jun 15;73(2-3):137-72 [11516494.001]
  • [Cites] Lasers Surg Med. 2001;29(4):314-22 [11746108.001]
  • [Cites] J Control Release. 2002 Feb 19;79(1-3):165-72 [11853928.001]
  • [Cites] J Drug Target. 2002 Aug;10(5):429-37 [12442814.001]
  • [Cites] Lasers Surg Med. 2003;32(1):61-8 [12516073.001]
  • [Cites] Ann Thorac Surg. 2003 Mar;75(3):952-9 [12645723.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):380-7 [12724736.001]
  • [Cites] Pharm Res. 2003 Apr;20(4):668-73 [12739777.001]
  • [Cites] J Pharm Sci. 2004 Jan;93(1):132-43 [14648643.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Jan 13;56(1):9-16 [14706442.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 2003;20(5):357-403 [14959789.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):138-46 [15185355.001]
  • [Cites] Cancer Res. 1981 Aug;41(8):3228-32 [7248977.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Cancer Res. 1988 Sep 1;48(17):4827-33 [3409223.001]
  • [Cites] Pharm Res. 1998 Oct;15(10):1552-6 [9794497.001]
  • (PMID = 18597164.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caproates; 0 / Lactones; 0 / Liposomes; 0 / Mesoporphyrins; 0 / Micelles; 0 / Photosensitizing Agents; 30IQX730WE / Polyethylene Glycols; 502-44-3 / caprolactone; 9004-74-4 / monomethoxypolyethylene glycol; EC 3.1.1.3 / Lipase; FU21S769PF / temoporfin
  • [Other-IDs] NLM/ PMC2515570
  •  go-up   go-down


87. de Parades V, Bauer P, Benbunan JL, Bouillet T, Cottu PH, Cuenod CA, Durdux C, Fléjou JF, Atienza P: [Initial pretherapeutic assessment of anal epidermoid carcinoma]. Gastroenterol Clin Biol; 2007 Feb;31(2):157-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Initial pretherapeutic assessment of anal epidermoid carcinoma].
  • [Transliterated title] Bilan préthérapeutique initial du carcinome épidermoïde invasif de l'anus.
  • Anal epidermoid carcinoma is a rare malignant tumor, comprising less than 5% of all carcinomas of the colon, rectum, and anus.
  • In addition, magnetic resonance imaging, positron emission tomography scanning and inguinal sentinel lymph node procedure should play a role in a more selective approach in patients with anal carcinoma.
  • [MeSH-major] Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347624.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 96
  •  go-up   go-down


88. Robb BW, Mutch MG: Epidermoid carcinoma of the anal canal. Clin Colon Rectal Surg; 2006 May;19(2):54-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid carcinoma of the anal canal.
  • Anal cancers are rare tumors with only an expected 4000 new diagnoses in 2005.
  • The majority of these are epidermoid or squamous cell cancers.
  • Nigro's description in 1974 of the use of a nonoperative treatment strategy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1153-60 [2599903.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] Br J Surg. 2005 May;92(5):605-14 [15739215.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):480-8 [13329997.001]
  • [Cites] Arch Surg. 1964 Dec;89:989-94 [14208473.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):127-31 [10219805.001]
  • [Cites] Acta Oncol. 1997;36(8):799-802 [9482685.001]
  • [Cites] Cancer. 1999 Aug 1;86(3):405-9 [10430247.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1488-93 [9860327.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 2;90(17):1300-2 [9731737.001]
  • [Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1101-5 [9169819.001]
  • [Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]
  • [Cites] Br J Cancer. 1997;75(5):722-8 [9043031.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(5):319-22 [8934052.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] J Pathol. 1996 Dec;180(4):378-82 [9014857.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1569-79 [8156483.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Lancet. 1994 Mar 12;343(8898):636-9 [7906812.001]
  • [Cites] N Engl J Med. 1994 Aug 4;331(5):300-2 [8022440.001]
  • [Cites] Obstet Gynecol. 1994 Feb;83(2):205-11 [8290181.001]
  • [Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1385-7 [1938540.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):180-9 [1311142.001]
  • [Cites] Arch Surg. 1992 Jun;127(6):741-4 [1317698.001]
  • [Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]
  • [Cites] Am J Med. 1985 Feb;78(2):211-5 [3918441.001]
  • [Cites] Gastroenterology. 1988 Jul;95(1):107-11 [2836255.001]
  • [Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]
  • [Cites] N Engl J Med. 1986 Oct 23;315(17):1089-90 [3020406.001]
  • [Cites] Am J Clin Pathol. 1989 Jul;92(1):16-21 [2546419.001]
  • [Cites] J Natl Cancer Inst. 1989 Nov 15;81(22):1726-31 [2810388.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):806-10 [2765832.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):611-6 [3524788.001]
  • [Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]
  • [Cites] Cancer. 1984 Jul 1;54(1):114-25 [6326995.001]
  • [Cites] Br J Cancer. 1983 Nov;48(5):629-36 [6639856.001]
  • [Cites] JAMA. 1982 Apr 9;247(14):1988-90 [7062503.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1425-9 [12390386.001]
  • [Cites] Dis Colon Rectum. 2001 Oct;44(10):1496-502 [11598480.001]
  • [Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]
  • [Cites] Eur J Cancer. 2000 Apr;36(6):754-8 [10762748.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1141-51 [2599902.001]
  • (PMID = 20011311.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780104
  • [Keywords] NOTNLM ; Epidermoid cancer / anal canal / squamous cancer
  •  go-up   go-down


89. Heitland W: [Diagnosis and therapy for anal carcinoma]. Chirurg; 2008 Feb;79(2):183-91; quiz 192
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and therapy for anal carcinoma].
  • [Transliterated title] Diagnostik und Therapie des Analkarzinoms.
  • Of all carcinomas in the anal canal, 75-80% are squamous cell carcinomas-the remaining 25% being adenocarcinomas.
  • Carcinomas of the anal margin are to be differentiated from basal cell carcinomas and Paget's and Bowen's diseases.
  • More than 80% of anal carcinomas show high-risk HP viruses.
  • Every suspicious lesion in the anal canal and margins must be examined histologically.
  • Primary radiochemotherapy is the first treatment option for epidermoid carcinomas of the anal canal and anal margin.
  • [MeSH-major] Anus Neoplasms / surgery
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Combined Modality Therapy. Humans. Lymph Node Excision. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Aug 1;54(3):411-5 [6329504.001]
  • [Cites] J Gastrointest Surg. 2001 Jul-Aug;5(4):383-7 [11985979.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):45-51 [12504657.001]
  • [Cites] Dis Colon Rectum. 2005 Jan;48(1):16-22 [15690652.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Dis Colon Rectum. 2004 Jul;47(7):1136-44 [15164245.001]
  • [Cites] World J Surg. 2005 Nov;29(11):1452-7 [16222445.001]
  • [Cites] Dis Colon Rectum. 2005 Sep;48(9):1742-51 [15991058.001]
  • [Cites] Cancer. 1984 Nov 15;54(10):2062-8 [6435851.001]
  • [Cites] Colorectal Dis. 2006 Feb;8(2):124-9 [16412072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):478-83 [17103253.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Am J Surg. 1985 Jan;149(1):95-101 [3966647.001]
  • [Cites] Ann Surg. 1976 Oct;184(4):422-8 [189707.001]
  • [Cites] Ann Surg. 1994 Jul;220(1):40-9 [8024357.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • (PMID = 18227955.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Hu S, Arellano M, Boontheung P, Wang J, Zhou H, Jiang J, Elashoff D, Wei R, Loo JA, Wong DT: Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res; 2008 Oct 1;14(19):6246-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salivary proteomics for oral cancer biomarker discovery.
  • PURPOSE: This study aims to explore the presence of informative protein biomarkers in the human saliva proteome and to evaluate their potential for detection of oral squamous cell carcinoma (OSCC).
  • The discovery of these new targets may lead to a simple clinical tool for the noninvasive diagnosis of oral cancer.
  • Long-term longitudinal studies with large populations of individuals with oral cancer and those who are at high risk of developing oral cancer are needed to validate these potential biomarkers.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genomics Proteomics. 2007 Mar-Apr;4(2):55-64 [17804867.001]
  • [Cites] Expert Rev Proteomics. 2007 Aug;4(4):531-8 [17705710.001]
  • [Cites] Mol Cell Proteomics. 2008 Mar;7(3):486-98 [18045803.001]
  • [Cites] J Proteome Res. 2008 May;7(5):1994-2006 [18361515.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):1-5 [10585574.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4915-20 [11156252.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1323-6 [11320393.001]
  • [Cites] J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 [11459866.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2535-9 [11980646.001]
  • [Cites] World J Gastroenterol. 2003 Apr;9(4):650-4 [12679903.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1380-2 [12958361.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):23-30 [14618611.001]
  • [Cites] Proteomics. 2004 Jan;4(1):271-8 [14730689.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2465-75 [15274141.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] Ann N Y Acad Sci. 1993 Sep 20;694:72-7 [8215087.001]
  • [Cites] Eur J Biochem. 1994 May 1;221(3):917-25 [8181474.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1054-9 [9353179.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):390-1 [9766578.001]
  • [Cites] Curr Opin Oncol. 1999 Sep;11(5):419-25 [10505783.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8442-50 [15623624.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3218-25 [15833853.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] Adv Dent Res. 2005 Jun;18(1):3-5 [16000263.001]
  • [Cites] Annu Rev Nutr. 2005;25:261-95 [16011468.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3173-82 [16035111.001]
  • [Cites] Anal Chem. 2005 Oct 1;77(19):6218-24 [16194081.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1459-70 [16037072.001]
  • [Cites] J Am Dent Assoc. 2006 Mar;137(3):313-21 [16570464.001]
  • [Cites] J Proteome Res. 2006 Jun;5(6):1493-503 [16740002.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3979-84 [16818695.001]
  • [Cites] J Cell Biochem. 2006 Aug 1;98(5):1351-66 [16518858.001]
  • [Cites] Rheumatology (Oxford). 2006 Sep;45(9):1077-86 [16522680.001]
  • [Cites] Proteomics. 2006 Nov;6(22):6107-16 [17051643.001]
  • [Cites] J Dent Res. 2006 Dec;85(12):1129-33 [17122167.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):813-20 [17131321.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):153-4 [17234527.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Feb;103(2):231-9 [17234541.001]
  • [Cites] J Oral Pathol Med. 2007 Feb;36(2):83-7 [17238969.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Feb 15;847(1):3-11 [17023222.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1179-85 [17317827.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1348-55 [17627000.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3588-600 [17968930.001]
  • (PMID = 18829504.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / R01 DE017170-01A2; United States / NCI NIH HHS / CA / R21 CA122806; United States / NCI NIH HHS / CA / R21 CA 122806; United States / NCI NIH HHS / CA / R21 CA122806-02; United States / NIDCR NIH HHS / DE / R01 DE015970; United States / NIDCR NIH HHS / DE / R01 DE017170; United States / NIDCR NIH HHS / DE / R01 DE 17170; United States / NIDCR NIH HHS / DE / R03 DE 017144; United States / NIDCR NIH HHS / DE / R03 DE017144-02; United States / NIDCR NIH HHS / DE / DE017170-01A2; United States / NIDCR NIH HHS / DE / R01 DE015970-01; United States / NIDCR NIH HHS / DE / R01 DE 15970; United States / NIDCR NIH HHS / DE / DE015970-01; United States / NIDCR NIH HHS / DE / R03 DE017144
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Polymers
  • [Other-IDs] NLM/ NIHMS92330; NLM/ PMC2877125
  •  go-up   go-down


91. Malhotra R, Patel V, Vaqué JP, Gutkind JS, Rusling JF: Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification. Anal Chem; 2010 Apr 15;82(8):3118-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultrasensitive electrochemical immunosensor for oral cancer biomarker IL-6 using carbon nanotube forest electrodes and multilabel amplification.
  • Squamous cell carcinomas of head and neck (HNSCC) are associated with immune, inflammatory, and angiogenic responses involving interleukin-6 (IL-6).

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2000 Jan;46(1):105-11 [10620578.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2422-8 [17438101.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):1911-28 [17849470.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Dec;19(10):769-76 [17950585.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):268-78 [18337732.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):571-9 [18385731.001]
  • [Cites] Analyst. 2008 Aug;133(8):975-83 [18645635.001]
  • [Cites] J Nanosci Nanotechnol. 2009 Jan;9(1):249-55 [19441303.001]
  • [Cites] Ann Clin Biochem. 2001 Nov;38(Pt 6):633-51 [11732646.001]
  • [Cites] Anal Chem. 2009 Nov 1;81(21):9129-34 [19775154.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2948-56 [12782602.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:133-9 [14656269.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):179-96 [15113093.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:9-16 [15251933.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):249-58 [15352037.001]
  • [Cites] J Clin Chem Clin Biochem. 1979 Jan;17(1):1-7 [33227.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mol Cell Endocrinol. 2005 Jan 31;230(1-2):95-106 [15664456.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Annu Rev Immunol. 2005;23:1-21 [15771564.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2761-5 [16080523.001]
  • [Cites] Int J Exp Pathol. 2005 Dec;86(6):347-63 [16309541.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):310-20 [16582876.001]
  • [Cites] Anal Chem. 2006 Jul 1;78(13):4260-9 [16856252.001]
  • [Cites] Mol Biosyst. 2005 May;1(1):70-8 [16880966.001]
  • [Cites] J Am Chem Soc. 2006 Aug 30;128(34):11199-205 [16925438.001]
  • [Cites] Analyst. 2007 Aug;132(8):724-37 [17646870.001]
  • (PMID = 20192182.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES013557; United States / NIEHS NIH HHS / ES / ES013557-04; United States / Intramural NIH HHS / / ; United States / NIEHS NIH HHS / ES / ES013557; United States / NIEHS NIH HHS / ES / R01 ES013557-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-6; 0 / Nanotubes, Carbon
  • [Other-IDs] NLM/ NIHMS183623; NLM/ PMC2854872
  •  go-up   go-down


92. Corner C, Bryant L, Chapman C, Glynne-Jones R, Hoskin PJ: High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. Brachytherapy; 2010 Jan-Mar;9(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma.
  • METHODS: Between 1993 and 2007, 79 patients were treated with HDR afterloading brachytherapy for rectal cancer; 70 patients had adenocarcinoma of the rectum; and 9 patients had squamous cell carcinoma of the anal canal.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Squamous Cell / radiotherapy. Rectal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19846349.001).
  • [ISSN] 1873-1449
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Fuller CD, Thomas CR Jr: Chemoradiation for anal cancer: the more things change, the more they stay the same. Oncology (Williston Park); 2010 Apr 30;24(5):427-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoradiation for anal cancer: the more things change, the more they stay the same.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2010 Apr 30;24(5):417-24 [20480740.001]
  • (PMID = 20480742.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


94. Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr; 2005 Dec 1;40(4):451-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic.
  • Squamous cell carcinoma of the anal canal (SCCA) is etiologically linked to human papillomavirus, and its incidence is increased among the immunosuppressed.
  • [MeSH-major] Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Infections / epidemiology


95. Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, Da Costa M, Darragh T, Benet DJ, Judson F, Koblin B, Mayer KH, Palefsky JM: Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst; 2005 Jun 15;97(12):896-905
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study.
  • BACKGROUND: Infection with human papillomavirus (HPV) is causally linked to the development of anal and cervical cancer.
  • In the United States, the incidence of anal cancer among men who have sex with men (MSM) is higher than the incidence of cervical cancer among women.
  • Anal squamous intraepithelial lesions (ASILs) are anal cancer precursors comprising low-grade squamous intraepithelial lesions (LSILs) and high-grade squamous intraepithelial lesions (HSILs).
  • The prevalence of cervical cancer precursor lesions peaks at around 30 years of age.
  • Anal cytology and behavioral data were obtained.
  • Anal HPV infection status was assessed by polymerase chain reaction.
  • In a multivariable analysis, the risk of LSILs was associated with having more than five male receptive anal sex partners (P = .03), any use of poppers (alkyl nitrites) in the previous 6 months [odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.1 to 2.5; P = .03] or use of injection drugs two or more times per month during the previous 6 months [OR = 19, 95% CI = 1.3 to 277; P = .03], older age at first receptive anal intercourse (P = .004), and infection with a greater number of HPV types (P < .001 for linear trend).
  • The risk of HSILs was associated with any anal HPV infection (OR = 3.2, 95% CI = 1.1 to 9.4; P = .039) and infection with an increasing number of HPV types (P < .001 for linear trend).
  • [MeSH-major] Aging. Anus Neoplasms / epidemiology. Carcinoma, Squamous Cell / epidemiology. Homosexuality, Male. Papillomaviridae. Papillomavirus Infections / epidemiology. Precancerous Conditions / epidemiology

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956651.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 M01-RR-00079; United States / NIAID NIH HHS / AI / 5 U01 AI46749; United States / NIAID NIH HHS / AI / K23 AI054157; United States / NIAID NIH HHS / AI / N01 AI35176; United States / NIAID NIH HHS / AI / N01 AI45200; United States / NIAID NIH HHS / AI / R01 AI 88739; United States / NCI NIH HHS / CA / R01 CA 88739; United States / NCI NIH HHS / CA / R01 CA54053; United States / NIAID NIH HHS / AI / U01 AI47995; United States / NIAID NIH HHS / AI / U01 AI48016; United States / NIAID NIH HHS / AI / U01 AI48040
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


96. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • There is evidence for the role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the staging and management of cancer, with early reports of an increasing role in outcome prognostication in a number of tumours.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


97. Baudis M: Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer; 2007;7:226
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Related average imbalance patterns were found for clinically distinct entities, e.g. hepatocellular carcinomas (ca.) and ductal breast ca., as well as for histologically related entities (squamous cell ca. of different sites).
  • [MeSH-major] Carcinoma / genetics. Chromosome Aberrations. Chromosome Mapping

  • COS Scholar Universe. author profiles.
  • SciCrunch. BioSharing: Resource: Registry .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Genet. 1988 Nov;80(3):235-46 [3192213.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1410-8 [10604741.001]
  • [Cites] Int J Oncol. 2000 Feb;16(2):383-99 [10639584.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):871-8 [10702404.001]
  • [Cites] J Pathol. 2000 Nov;192(3):301-6 [11054712.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):399-406 [11159178.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Bioinformatics. 2001 Dec;17(12):1228-9 [11751233.001]
  • [Cites] Anal Cell Pathol. 2001;23(1):29-37 [11790857.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1381-7 [11830490.001]
  • [Cites] Cancer Genet Cytogenet. 2002 May;135(1):63-90 [12072205.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):77-87 [12446957.001]
  • [Cites] Int J Cancer. 2003 Jul 1;105(4):494-8 [12712440.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1808-14 [12738738.001]
  • [Cites] Pathologica. 2003 Apr;95(2):71-82 [12768875.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1039-44 [14730057.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] BMC Cancer. 2004 Feb 6;4:5 [15018632.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):143-9 [15140403.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Cytogenet Genome Res. 2004;106(1):43-8 [15218240.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):1-9 [15325087.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):682-7 [15483344.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Clin Genet. 1972;3(3):169-79 [4115505.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):584-9 [8383093.001]
  • [Cites] Trends Genet. 1993 Apr;9(4):138-41 [8516849.001]
  • [Cites] Hum Mol Genet. 1993 Nov;2(11):1907-14 [8281155.001]
  • [Cites] Am J Pathol. 1994 Aug;145(2):356-64 [7519827.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4813-7 [8062283.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Jul 15;82(2):140-5 [7664243.001]
  • [Cites] Blood. 1996 Jan 1;87(1):25-9 [8547649.001]
  • [Cites] Nat Genet. 1996 Apr;12(4):368-75 [8630489.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:101-4 [8981013.001]
  • [Cites] Cytogenet Cell Genet. 1996;75(1):17-21 [8995481.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):406-10 [9090389.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Sep;56(9):999-1008 [9291941.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):372-6 [9408753.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Feb;21(2):172-5 [9491330.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Am J Hum Genet. 1998 Aug;63(2):625-37 [9683604.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):307-16 [9824203.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1283-91 [16979954.001]
  • [Cites] Oncogene. 2006 Nov 23;25(55):7324-32 [16751803.001]
  • [Cites] J Pathol. 2007 Jan;211(1):18-25 [17072825.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):293-301 [17011066.001]
  • [Cites] Oncogene. 2007 Feb 8;26(6):934-44 [16862168.001]
  • [Cites] Bioinformatics. 2007 Feb 15;23(4):450-7 [17150994.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):1-14 [17382262.001]
  • [Cites] Prostate. 2007 May 15;67(7):692-700 [17342750.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2734-8 [17354231.001]
  • [Cites] Pathologe. 2007 Nov;28(6):464-73 [17882420.001]
  • [Cites] Ugeskr Laeger. 2008 Jan 28;170(5):328-30 [18252159.001]
  • [Cites] Hum Genet. 1988 Nov;80(3):224-34 [3192212.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Am J Hum Genet. 1960 Sep;12:250-76 [14430808.001]
  • [Cites] Thyroid. 2004 Dec;14(12):1061-4 [15650359.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):822-7 [15705879.001]
  • [Cites] Acta Pharmacol Sin. 2005 Jun;26(6):659-65 [15916730.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):593-606 [16077907.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):11-9 [16130125.001]
  • [Cites] Biotechniques. 2006 Mar;40(3):269-70, 272 [16568815.001]
  • [Cites] BMC Cancer. 2006;6:96 [16620391.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jun;167(2):103-8 [16737908.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Aug;45(8):721-30 [16688744.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12(13):3961-70 [16818693.001]
  • [Cites] Cell Oncol. 2006;28(3):71-84 [16823176.001]
  • [Cites] Oncogene. 2006 Jul 27;25(32):4399-412 [16547504.001]
  • [Cites] Bioinformatics. 2006 Aug 15;22(16):1971-8 [16705014.001]
  • [Cites] Cytogenet Genome Res. 2006;115(1):16-22 [16974079.001]
  • [Cites] J Invest Dermatol. 2006 Oct;126(10):2308-15 [16728973.001]
  • (PMID = 18088415.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2225423
  •  go-up   go-down


98. Abramowitz L, Mathieu N, Roudot-Thoraval F, Lemarchand N, Bauer P, Hennequin C, Mitry E, Romelaer C, Aparicio T, Sobhani I: Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. Aliment Pharmacol Ther; 2009 Aug 15;30(4):414-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients.
  • BACKGROUND: Previous studies suggest a poor prognosis of epidermoid anal cancer in HIV+ patients.
  • AIM: To investigate the long-term outcome of epidermoid anal cancer in HIV+ and HIV- patients in the highly active antiretroviral treatment (HAART) era.
  • METHODS: We included all patients with epidermoid anal cancer referred to six hospitals from 1998 to 2004.
  • CONCLUSIONS: The clinical outcome of HIV+ patients with epidermoid anal cancer is similar to that of HIV- patients.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / therapy. HIV Infections / drug therapy. HIV Seropositivity / complications


99. Anal cancer incidence rates increased in antiretroviral era. Rates increased for men and women. AIDS Alert; 2006 Mar;21(3):22-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anal cancer incidence rates increased in antiretroviral era. Rates increased for men and women.
  • Investigators compared United States surveillance data for cancer in the pre-HIV era, HIV era, and antiretroviral treatment era and found that squamous cell carcinoma of the anal canal incidence rates increased significantly in the latter era.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Anus Neoplasms / epidemiology. HIV Infections / drug therapy


100. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, Arzani D, De Lauretis A, Cattel C, Almadori G, van Duijn CM, Paludetti G, Ricciardi G: CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol; 2008 Jan;134(1):93-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer.
  • PURPOSE: As risk-modifiers of alcohol and tobacco effects, metabolic genes polymorphisms were investigated as susceptibility candidates for squamous cell carcinoma of the head and neck (SCCHN).
  • [MeSH-minor] Arylamine N-Acetyltransferase / genetics. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / prevention & control. Case-Control Studies. Cytochrome P-450 CYP1A1 / genetics. Cytochrome P-450 CYP2E1 / genetics. Epoxide Hydrolases / genetics. Exons / genetics. Female. Follow-Up Studies. Fruit. Genetic Predisposition to Disease. Genotype. Glutathione Transferase / genetics. Humans. Italy / epidemiology. Male. Middle Aged. Risk Management. Surveys and Questionnaires. Vegetables

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jul 1;110(4):598-604 [15122594.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):95-101 [12359356.001]
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):44-8 [10077151.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):101-6 [16837478.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1999;18(2):85-93 [15281219.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2293-7 [16331628.001]
  • [Cites] Am J Public Health. 2005;95 Suppl 1:S144-50 [16030331.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • [Cites] Oral Oncol. 1997 Sep;33(5):302-12 [9415327.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):127-35 [15685196.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Apr;7(4):341-6 [9568791.001]
  • [Cites] Pharmacogenetics. 2003 Apr;13(4):225-30 [12668919.001]
  • [Cites] Eur J Cancer Prev. 2003 Apr;12(2):135-43 [12671537.001]
  • [Cites] Arch Toxicol. 2003 Jan;77(1):37-41 [12491039.001]
  • [Cites] Lancet. 1997 Aug 30;350(9078):630-3 [9288046.001]
  • [Cites] Int J Cancer. 2000 Jul 1;87(1):129-32 [10861463.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):534-6 [10676631.001]
  • [Cites] Nutr Cancer. 2002;44(2):104-26 [12734057.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):112-23 [15914211.001]
  • [Cites] Pharmacogenetics. 1998 Apr;8(2):91-100 [10022746.001]
  • [Cites] J Clin Pathol. 1998 Apr;51(4):294-8 [9659241.001]
  • [Cites] Ann Oncol. 2003 Nov;14 (11):1677-81 [14581278.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):1034-6 [15824189.001]
  • [Cites] Mutat Res. 1999 May;436(3):227-61 [10354524.001]
  • [Cites] Public Health Nutr. 2004 Apr;7(2):257-61 [15003132.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):781-8 [11191882.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):102-18 [16023150.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):185-91 [10698480.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1006-11 [11920469.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1509-17 [14693745.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):992-5 [15986425.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):685-8 [10048967.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):606-9 [10521794.001]
  • [Cites] Eur J Cancer Prev. 2001 Apr;10(2):191-5 [11330465.001]
  • [Cites] Am J Clin Nutr. 2006 May;83(5):1126-34 [16685056.001]
  • [Cites] Eur J Epidemiol. 2005;20(7):575-9 [16119429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):106-15 [10889929.001]
  • (PMID = 17611777.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Enzymes; EC 1.14.13.- / Cytochrome P-450 CYP2E1; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 3.3.2.- / Epoxide Hydrolases; EC 3.3.2.9 / EPHX1 protein, human
  •  go-up   go-down






Advertisement